
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Impact of cilostazol on clinical outcomes in lower extremity arterial disease patients after angioplasty: A real-world analysis - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="1525444D8AF3005305444D0009DDC0E6.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="plosone">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12370041/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="PLOS One">
<meta name="citation_title" content="Impact of cilostazol on clinical outcomes in lower extremity arterial disease patients after angioplasty: A real-world analysis">
<meta name="citation_author" content="Hsien-Yuan Chang">
<meta name="citation_author_institution" content="Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan">
<meta name="citation_author_institution" content="Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan">
<meta name="citation_author" content="Hui-Wen Lin">
<meta name="citation_author_institution" content="Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan">
<meta name="citation_author" content="Po-Wei Chen">
<meta name="citation_author_institution" content="Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan">
<meta name="citation_author_institution" content="Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan">
<meta name="citation_author" content="Sheng-Hsiang Lin">
<meta name="citation_author_institution" content="Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan">
<meta name="citation_author_institution" content="Biostatistics Consulting Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan">
<meta name="citation_author_institution" content="Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan">
<meta name="citation_author" content="Ting-Hsing Chao">
<meta name="citation_author_institution" content="Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan">
<meta name="citation_author_institution" content="Division of Cardiology, Department of Internal Medicine, Chung-Shan Medical University Hospital, School of Medicine, Chung Shan Medical University, Taichung, Taiwan">
<meta name="citation_author" content="Yi-Heng Li">
<meta name="citation_author_institution" content="Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan">
<meta name="citation_publication_date" content="2025 Aug 21">
<meta name="citation_volume" content="20">
<meta name="citation_issue" content="8">
<meta name="citation_firstpage" content="e0330434">
<meta name="citation_doi" content="10.1371/journal.pone.0330434">
<meta name="citation_pmid" content="40839648">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12370041/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12370041/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12370041/pdf/pone.0330434.pdf">
<meta name="description" content="Cilostazol has been shown to improve walking distance in patients with lower extremity arterial disease (LEAD) and may reduce restenosis after revascularization. However, its long-term prognostic impact in real-world settings remains underexplored. ...">
<meta name="og:title" content="Impact of cilostazol on clinical outcomes in lower extremity arterial disease patients after angioplasty: A real-world analysis">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Cilostazol has been shown to improve walking distance in patients with lower extremity arterial disease (LEAD) and may reduce restenosis after revascularization. However, its long-term prognostic impact in real-world settings remains underexplored. ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12370041/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12370041">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1371/journal.pone.0330434"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/pone.0330434.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12370041%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12370041/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12370041/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12370041/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-plosone.png" alt="PLOS One logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to PLOS One" title="Link to PLOS One" shape="default" href="https://doi.org/10.1371/journal.pone.0330434" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">PLoS One</button></div>. 2025 Aug 21;20(8):e0330434. doi: <a href="https://doi.org/10.1371/journal.pone.0330434" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1371/journal.pone.0330434</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22PLoS%20One%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22PLoS%20One%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22PLoS%20One%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22PLoS%20One%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Impact of cilostazol on clinical outcomes in lower extremity arterial disease patients after angioplasty: A real-world analysis</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chang%20HY%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Hsien-Yuan Chang</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Hsien-Yuan Chang</span></h3>
<div class="p">
<sup>1</sup>Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan</div>
<div class="p">
<sup>2</sup>Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan</div>
<div>Conceptualization, Data curation, Investigation, Methodology, Project administration, Supervision, Writing – original draft</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chang%20HY%22%5BAuthor%5D" class="usa-link"><span class="name western">Hsien-Yuan Chang</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lin%20HW%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Hui-Wen Lin</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Hui-Wen Lin</span></h3>
<div class="p">
<sup>2</sup>Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan</div>
<div>Data curation, Formal analysis</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lin%20HW%22%5BAuthor%5D" class="usa-link"><span class="name western">Hui-Wen Lin</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chen%20PW%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Po-Wei Chen</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Po-Wei Chen</span></h3>
<div class="p">
<sup>1</sup>Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan</div>
<div class="p">
<sup>2</sup>Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan</div>
<div>Conceptualization, Validation, Writing – review &amp; editing</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chen%20PW%22%5BAuthor%5D" class="usa-link"><span class="name western">Po-Wei Chen</span></a>
</div>
</div>
<sup>1,</sup><sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lin%20SH%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Sheng-Hsiang Lin</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Sheng-Hsiang Lin</span></h3>
<div class="p">
<sup>1</sup>Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan</div>
<div class="p">
<sup>3</sup>Biostatistics Consulting Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan</div>
<div class="p">
<sup>4</sup>Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan</div>
<div>Data curation, Formal analysis, Methodology, Supervision, Validation</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Lin%20SH%22%5BAuthor%5D" class="usa-link"><span class="name western">Sheng-Hsiang Lin</span></a>
</div>
</div>
<sup>1,</sup><sup>3,</sup><sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chao%20TH%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Ting-Hsing Chao</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Ting-Hsing Chao</span></h3>
<div class="p">
<sup>2</sup>Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan</div>
<div class="p">
<sup>5</sup>Division of Cardiology, Department of Internal Medicine, Chung-Shan Medical University Hospital, School of Medicine, Chung Shan Medical University, Taichung, Taiwan</div>
<div>Conceptualization, Funding acquisition, Supervision, Writing – review &amp; editing</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chao%20TH%22%5BAuthor%5D" class="usa-link"><span class="name western">Ting-Hsing Chao</span></a>
</div>
</div>
<sup>2,</sup><sup>5,</sup><sup>*,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20YH%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Yi-Heng Li</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Yi-Heng Li</span></h3>
<div class="p">
<sup>2</sup>Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan</div>
<div>Conceptualization, Data curation, Supervision, Validation, Visualization, Writing – review &amp; editing</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Li%20YH%22%5BAuthor%5D" class="usa-link"><span class="name western">Yi-Heng Li</span></a>
</div>
</div>
<sup>2,</sup><sup>*,</sup><sup>#</sup>
</div>
<div class="cg p">Editor: <span class="name western">Timir Paul</span><sup>6</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="aff001">
<sup>1</sup>Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan</div>
<div id="aff002">
<sup>2</sup>Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan</div>
<div id="aff003">
<sup>3</sup>Biostatistics Consulting Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan</div>
<div id="aff004">
<sup>4</sup>Department of Public Health, College of Medicine, National Cheng Kung University, Tainan, Taiwan</div>
<div id="aff005">
<sup>5</sup>Division of Cardiology, Department of Internal Medicine, Chung-Shan Medical University Hospital, School of Medicine, Chung Shan Medical University, Taichung, Taiwan</div>
<div id="edit1">
<sup>6</sup>East Tennessee State University, UNITED STATES OF AMERICA</div>
<div class="author-notes p">
<div class="fn" id="coi001"><p><strong>Competing Interests: </strong>The authors have declared that no competing interests exist.</p></div>
<div class="fn" id="cor001">
<sup>✉</sup><p class="display-inline">* E-mail: <span>heng@mail.ncku.edu.tw</span> (YHL); <span>chaotinghsing@gmail.com</span> (THC)</p>
</div>
<div class="fn" id="_eqcntrb93pmc__">
<sup>#</sup><p class="display-inline">Contributed equally.</p>
</div>
</div>
<h4 class="font-secondary">Roles</h4>
<div class="p">
<strong class="contrib"><span class="name western">Hsien-Yuan Chang</span></strong>: <span class="role">Conceptualization, Data curation, Investigation, Methodology, Project administration, Supervision, Writing – original draft</span>
</div>
<div>
<strong class="contrib"><span class="name western">Hui-Wen Lin</span></strong>: <span class="role">Data curation, Formal analysis</span>
</div>
<div>
<strong class="contrib"><span class="name western">Po-Wei Chen</span></strong>: <span class="role">Conceptualization, Validation, Writing – review &amp; editing</span>
</div>
<div>
<strong class="contrib"><span class="name western">Sheng-Hsiang Lin</span></strong>: <span class="role">Data curation, Formal analysis, Methodology, Supervision, Validation</span>
</div>
<div>
<strong class="contrib"><span class="name western">Ting-Hsing Chao</span></strong>: <span class="role">Conceptualization, Funding acquisition, Supervision, Writing – review &amp; editing</span>
</div>
<div>
<strong class="contrib"><span class="name western">Yi-Heng Li</span></strong>: <span class="role">Conceptualization, Data curation, Supervision, Validation, Visualization, Writing – review &amp; editing</span>
</div>
<div class="p">
<strong class="contrib"><span class="name western">Timir Paul</span></strong>: <span class="role">Editor</span>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 May 9; Accepted 2025 Jul 31; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© 2025 Chang et al</div>
<p>This is an open access article distributed under the terms of the <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12370041  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40839648/" class="usa-link">40839648</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<section id="sec001"><h3 class="pmc_sec_title">Background</h3>
<p>Cilostazol has been shown to improve walking distance in patients with lower extremity arterial disease (LEAD) and may reduce restenosis after revascularization. However, its long-term prognostic impact in real-world settings remains underexplored.</p></section><section id="sec002"><h3 class="pmc_sec_title">Methods</h3>
<p>We conducted a retrospective cohort study using data from Taiwan's National Health Insurance Research Database (2012–2022). We included stable LEAD patients who had undergone percutaneous transluminal angioplasty (PTA) and remained event-free for 1 year. Stabilized inverse probability of treatment weighting (IPTW) was applied to adjust for baseline confounders. The study aimed to evaluate the effect of cilostazol on major adverse cardiovascular events (MACE), major adverse limb events (MALE), and composite bleeding outcomes.</p></section><section id="sec003"><h3 class="pmc_sec_title">Results</h3>
<p>Among 5,300 stable LEAD patients, of whom 844 received cilostazol alone, 1,786 received aspirin or clopidogrel, and 2,670 received cilostazol combined with aspirin or clopidogrel. After IPTW, there were no significant differences between cilostazol monotherapy and any antiplatelet therapy groups regarding MACE, MALE, or composite bleeding outcomes (aHR [95% CI] = 0.84 [0.68–1.03], p = 0.09; 0.84 [0.70–1.01], p = 0.06; 0.88 [0.71–1.10], p = 0.26, respectively). In secondary outcomes, cilostazol treatment was associated with a reduced rate of subsequent angioplasty (aHR [95% CI] = 0.80 [0.60–0.98], p = 0.03). There were no significant differences in clinical outcomes when comparing cilostazol monotherapy to cilostazol combined with antiplatelet therapy.</p></section><section id="sec004"><h3 class="pmc_sec_title">Conclusion</h3>
<p>In this real-world Asian cohort, cilostazol showed similar prognostic benefits and safety compared to standard antiplatelet therapy. These findings support its role in the long-term management of LEAD patients following PTA, particularly in Asian populations.</p></section></section><section id="sec005"><h2 class="pmc_sec_title">Introduction</h2>
<p>Lower extremity arterial disease (LEAD) ranks as the third leading cause of death among individuals with atherosclerotic cardiovascular diseases, following coronary artery disease and stroke. In recent years, advancements in endovascular revascularization have positioned it as a cornerstone in the management of symptomatic LEAD, especially for patients with intermittent claudication or critical limb ischemia. However, despite the initial technical success of these interventions, high rates of restenosis and recurrent symptoms remain prevalent. [<a href="#pone.0330434.ref001" class="usa-link" aria-describedby="pone.0330434.ref001">1</a>] These challenges underscore the importance of implementing guideline-directed medical therapy to optimize long-term clinical outcomes and maintain vascular patency following revascularization [<a href="#pone.0330434.ref002" class="usa-link" aria-describedby="pone.0330434.ref002">2</a>–<a href="#pone.0330434.ref004" class="usa-link" aria-describedby="pone.0330434.ref004">4</a>]</p>
<p>Cilostazol, a phosphodiesterase 3 inhibitor with antiplatelet and vasodilatory properties, is commonly used in LEAD patients to alleviate the symptoms of intermittent claudication and to reduce post-angioplasty restenosis. Several recent randomized controlled trials have demonstrated its efficacy in lowering late lumen loss and reducing the need for target lesion revascularization. [<a href="#pone.0330434.ref005" class="usa-link" aria-describedby="pone.0330434.ref005">5</a>] Beyond its vascular benefits, cilostazol has shown promising effects on angiogenesis in preclinical studies, [<a href="#pone.0330434.ref006" class="usa-link" aria-describedby="pone.0330434.ref006">6</a>–<a href="#pone.0330434.ref008" class="usa-link" aria-describedby="pone.0330434.ref008">8</a>] and emerging evidence suggests its potential in reducing major adverse cardiovascular events (MACE) [<a href="#pone.0330434.ref009" class="usa-link" aria-describedby="pone.0330434.ref009">9</a>,<a href="#pone.0330434.ref010" class="usa-link" aria-describedby="pone.0330434.ref010">10</a>]. However, despite these findings, current clinical guidelines do not recommend cilostazol for the explicit purpose of MACE reduction, [<a href="#pone.0330434.ref002" class="usa-link" aria-describedby="pone.0330434.ref002">2</a>] and the European Society of Cardiology guidelines make no recommendation of cilostazol at all in the context of LEAD management. [<a href="#pone.0330434.ref004" class="usa-link" aria-describedby="pone.0330434.ref004">4</a>] Notably, although randomized controlled trials have highlighted the potential benefits of cilostazol, evidence from real-world clinical practice—particularly among LEAD patients following angioplasty—remains relatively limited. This discrepancy between trial-based findings and current clinical guideline recommendations invites further investigation into cilostazol’s role in the management of LEAD in routine care settings.</p>
<p>Therefore, this study aims to compare cilostazol with other current antiplatelet therapies using real-world data, evaluating their impact on clinical outcomes, including MACE and major adverse limb events (MALE), in patients with LEAD undergoing endovascular revascularization in a real-world setting.</p></section><section id="sec006"><h2 class="pmc_sec_title">Methods</h2>
<section id="sec007"><h3 class="pmc_sec_title">Study design</h3>
<p>This is a retrospective cohort study using data from the National Health Insurance Research Database in Taiwan, which were accessed and processed for research purposes between November 1, 2024, and March 31, 2025, covering the period from January 1, 2012, to December 31, 2022. This study adhered to the Declaration of Helsinki and received approval from the Institutional Review Board of the National Cheng Kung University Hospital (IRB number: A-EX-113–007). The requirement for informed consent was waived owing to the retrospective design of the study. All data were fully anonymized before access, and the authors did not have access to any information that could identify individual participants during or after data collection</p></section><section id="sec008"><h3 class="pmc_sec_title">Study population and inclusion criteria</h3>
<p>We enrolled adult patients who were newly diagnosed with LEAD and underwent percutaneous transluminal angioplasty (PTA). Medical information was recorded using the International Classification of Diseases, Ninth and Tenth Revisions, Clinical Modification (ICD-9-CM and ICD-10-CM) codes. Patients diagnosed with LEAD were identified using the following codes: ICD-9-CM codes (443.9, 440.2, 440.3, 440.4) and ICD-10-CM codes (I65.9, I63.00, I63.10, I63.20, I63.29, I73.9, I70.2, I70.3, I70.4, I70.5, I70.6, I70.7, I70.8). Patients who underwent PTA were identified using the following codes: ICD-9-CM codes (38.08, 38.18, 38.38, 38.48, 38.58, 35.68, 38.88, 39.50, 39.7, 39.90, 39.25, 39.26, 39.29) and ICD-10-CM codes (041, 045, 047, 049, 04B, 04C, 04H, 04J, 04L, 04N, 04P, 04Q, 04R, 04S, 04U, 04V, 04W).</p>
<p>In line with current guidelines that recommend dual antiplatelet therapy (DAPT) for 1–3 months post-PTA, [<a href="#pone.0330434.ref002" class="usa-link" aria-describedby="pone.0330434.ref002">2</a>,<a href="#pone.0330434.ref004" class="usa-link" aria-describedby="pone.0330434.ref004">4</a>] To avoid immortal time bias, a landmark design was employed, [<a href="#pone.0330434.ref011" class="usa-link" aria-describedby="pone.0330434.ref011">11</a>] with the index date set between six months and one year after PTA. Clinical information collected during the index date included age, sex, comorbidities, and medications. Detailed corresponding ICD codes are listed in Supplemental Table 1. Patients were grouped according to the medications they were using at the index date. To focus the analysis on the long-term effects of the medications on clinical outcomes, patients who experienced major adverse cardiovascular events (MACE) within the first year following PTA or major adverse limb events (MALE) between six months and one year post-angioplasty were excluded from the study (Supplemental Fig 1). Additional exclusion criteria included medication records of fewer than 84 days within the index date, use of aspirin plus clopidogrel, previous history of atrial fibrillation, or other indications for novel oral anticoagulants or warfarin.</p></section><section id="sec009"><h3 class="pmc_sec_title">Clinical outcomes</h3>
<p>Clinical outcomes were recorded starting from one year after PTA. Detailed corresponding ICD codes are listed in Supplemental Table 1. The primary endpoint was the incidence of MACE, defined as a composite outcome of cardiovascular death, non-fatal myocardial infarction, stroke, or transient ischemic attack. The co-primary endpoint was the incidence of MALE, defined as a composite outcome of undergoing PTA for LEAD or amputation. The secondary endpoints were cardiovascular death, non-fatal myocardial infarction, stroke or transient ischemic attack, undergoing PTA for LEAD, and amputation. The safety outcome was a composite of bleeding events, including hemorrhagic stroke, gastrointestinal bleeding, or other site bleeding.</p></section><section id="sec010"><h3 class="pmc_sec_title">Statistical analysis</h3>
<p>Continuous data are presented as mean ± standard deviation, while categorical data are expressed as frequencies and percentages. Comparisons among the three groups were conducted using one-way ANOVA for normally distributed continuous variables, and the Kruskal–Wallis test for non-normally distributed variables. For categorical variables, either the chi-square test or Fisher’s exact test was applied, as appropriate. To minimize confounding due to baseline differences among groups, stabilized inverse probability of treatment weighting (IPTW) was applied. Propensity scores were estimated using a multinomial logistic regression model based on baseline covariates, including age, gender, times of PTA, comorbidities (hypertension, diabetes mellitus, dyslipidemia, coronary artery disease, chronic kidney disease, end stage renal disease), and medications (statin, beta blocker, etc.). Stabilized weights were calculated as the marginal probability of group assignment divided by the propensity score for each individual. These weights were used to construct a pseudopopulation in which the distribution of baseline covariates was balanced across the three groups. After applying IPTW, covariate balance among the three groups was assessed using one-way ANOVA or Kruskal–Wallis tests for continuous variables and chi-square or Fisher’s exact tests for categorical variables. These comparisons ensured that the weighted sample achieved adequate balance in baseline characteristics.</p>
<p>Cox proportional hazards models were used to estimate hazard ratios and 95% confidence intervals for outcomes across the groups. Both IPTW-weighted and unweighted models were constructed. In the unweighted models, multivariable adjustment for the aforementioned baseline covariates was performed. The proportional hazards assumption was verified prior to model fitting. A two-sided p-value &lt; 0.05 was considered statistically significant. All statistical analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC, USA).</p></section></section><section id="sec011"><h2 class="pmc_sec_title">Results</h2>
<section id="sec012"><h3 class="pmc_sec_title">Study population</h3>
<p>A total of 17,993 patients diagnosed with LEAD and treated with PTA were retrospectively screened. Of these, 7,760 patients were excluded due to the occurrence of MACE within one year or MALE on the index date. After applying additional exclusion criteria, a final cohort of 5,300 patients was included in the analysis (mean age: 71 ± 12 years; 61% male). Among these patients, 1,786 (34%) received aspirin or clopidogrel monotherapy, 844 (16%) received cilostazol monotherapy, and 2,670 (50%) were treated with cilostazol in combination with aspirin or clopidogrel (<a href="#pone.0330434.g001" class="usa-link">Fig 1</a>). The most notable baseline difference was the prevalence of coronary artery disease (CAD), which was significantly lower in the cilostazol group compared to the others (29% vs. 52%, <em>p</em> &lt; 0.01, <a href="#pone.0330434.t001" class="usa-link">Table 1</a>). This finding is clinically reasonable, as current guidelines recommend aspirin or clopidogrel for patients with CAD, making them less likely to be prescribed cilostazol monotherapy. In addition, despite their now-recognized therapeutic potential in the management of LEAD, newer pharmacological agents such as rivaroxaban 2.5 mg, sodium-glucose cotransporter 2 (SGLT2) inhibitors, and glucagon-like peptide-1 (GLP-1) receptor agonists were prescribed in only 1–3% of patients in this real-world dataset. This likely reflects the treatment patterns of the earlier period during which the data were collected, prior to the widespread adoption of these agents based on more recent clinical evidence.</p>
<figure class="fig xbox font-sm" id="pone.0330434.g001"><h4 class="obj_head">Fig 1. Flow diagram of the study cohort.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12370041_pone.0330434.g001.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20bc/12370041/881104fcbcfc/pone.0330434.g001.jpg" loading="lazy" height="412" width="681" alt="Fig 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/pone.0330434.g001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>(MACE: major adverse cardiovascular events; MALE: major adverse limb events; N: number of participants; NOAC: Novel oral anticoagulants; PTA: percutaneous transluminal angioplasty).</p></figcaption></figure><section class="tw xbox font-sm" id="pone.0330434.t001"><h4 class="obj_head">Table 1. The baseline characteristics of LEAD patients treated with before and after inverse probability of treatment weighting (IPTW).</h4>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
</colgroup>
<thead>
<tr>
<th align="left" rowspan="1" colspan="1"></th>
<th align="left" rowspan="1" colspan="1"></th>
<th align="left" rowspan="1" colspan="1"></th>
<th align="left" colspan="11" rowspan="1">Inverse probability of treatment weighting</th>
</tr>
<tr>
<th align="left" rowspan="1" colspan="1"></th>
<th align="left" rowspan="1" colspan="1"></th>
<th align="left" rowspan="1" colspan="1"></th>
<th align="left" colspan="7" rowspan="1">Before</th>
<th align="left" colspan="4" rowspan="1">After</th>
</tr>
<tr>
<th align="left" rowspan="2" colspan="1"></th>
<th align="left" colspan="2" rowspan="1">Total</th>
<th align="left" colspan="2" rowspan="1">Aspirin or Plavix users</th>
<th align="left" colspan="2" rowspan="1">Cilostazol users</th>
<th align="left" colspan="2" rowspan="1">Aspirin+Cilostazol or Plavix+Cilostazol</th>
<th align="left" rowspan="2" colspan="1">P</th>
<th align="left" rowspan="1" colspan="1">Aspirin or Plavix users</th>
<th align="left" rowspan="1" colspan="1">Cilostazol users</th>
<th align="left" rowspan="1" colspan="1">Aspirin+Cilostazol or Plavix+Cilostazol</th>
<th align="left" rowspan="2" colspan="1">P</th>
</tr>
<tr>
<th align="left" colspan="2" rowspan="1">N = 5300</th>
<th align="left" colspan="2" rowspan="1">N = 1786</th>
<th align="left" colspan="2" rowspan="1">N = 844</th>
<th align="left" colspan="2" rowspan="1">N = 2670</th>
<th align="left" rowspan="1" colspan="1">N = pseudo data</th>
<th align="left" rowspan="1" colspan="1">N = pseudo data</th>
<th align="left" rowspan="1" colspan="1">N = pseudo data</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">Age (mean ± SD)</td>
<td align="left" colspan="2" rowspan="1">71.21 ± 11.61</td>
<td align="left" colspan="2" rowspan="1">70.78 ± 11.43</td>
<td align="left" colspan="2" rowspan="1">72.21 ± 12.30</td>
<td align="left" colspan="2" rowspan="1">71.19 ± 11.49</td>
<td align="left" rowspan="1" colspan="1">0.34</td>
<td align="left" rowspan="1" colspan="1">71.13 ± 11.51</td>
<td align="left" rowspan="1" colspan="1">71.00 ± 12.01</td>
<td align="left" rowspan="1" colspan="1">71.23 ± 11.51</td>
<td align="left" rowspan="1" colspan="1">0.39</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Gender (Male)</td>
<td align="left" rowspan="1" colspan="1">3251</td>
<td align="left" rowspan="1" colspan="1">(61.34)</td>
<td align="left" rowspan="1" colspan="1">1136</td>
<td align="left" rowspan="1" colspan="1">(63.61)</td>
<td align="left" rowspan="1" colspan="1">471</td>
<td align="left" rowspan="1" colspan="1">(55.81)</td>
<td align="left" rowspan="1" colspan="1">1644</td>
<td align="left" rowspan="1" colspan="1">(61.57)</td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1">61.47</td>
<td align="left" rowspan="1" colspan="1">62.12</td>
<td align="left" rowspan="1" colspan="1">61.42</td>
<td align="left" rowspan="1" colspan="1">0.94</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Times of PTA</td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1">&lt;0.01</td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1">0.89</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">4443</td>
<td align="left" rowspan="1" colspan="1">(83.83)</td>
<td align="left" rowspan="1" colspan="1">1554</td>
<td align="left" rowspan="1" colspan="1">(87.01)</td>
<td align="left" rowspan="1" colspan="1">729</td>
<td align="left" rowspan="1" colspan="1">(86.37)</td>
<td align="left" rowspan="1" colspan="1">2160</td>
<td align="left" rowspan="1" colspan="1">(80.90)</td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1">83.72</td>
<td align="left" rowspan="1" colspan="1">84.53</td>
<td align="left" rowspan="1" colspan="1">83.79</td>
<td align="left" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">746</td>
<td align="left" rowspan="1" colspan="1">(14.08)</td>
<td align="left" rowspan="1" colspan="1">207</td>
<td align="left" rowspan="1" colspan="1">(11.59)</td>
<td align="left" rowspan="1" colspan="1">100</td>
<td align="left" rowspan="1" colspan="1">(11.85)</td>
<td align="left" rowspan="1" colspan="1">439</td>
<td align="left" rowspan="1" colspan="1">(16.44)</td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1">14.15</td>
<td align="left" rowspan="1" colspan="1">12.95</td>
<td align="left" rowspan="1" colspan="1">14.18</td>
<td align="left" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">≥3</td>
<td align="left" rowspan="1" colspan="1">111</td>
<td align="left" rowspan="1" colspan="1">(2.09)</td>
<td align="left" rowspan="1" colspan="1">25</td>
<td align="left" rowspan="1" colspan="1">(1.40)</td>
<td align="left" rowspan="1" colspan="1">15</td>
<td align="left" rowspan="1" colspan="1">(1.78)</td>
<td align="left" rowspan="1" colspan="1">71</td>
<td align="left" rowspan="1" colspan="1">(2.66)</td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1">2.13</td>
<td align="left" rowspan="1" colspan="1">2.51</td>
<td align="left" rowspan="1" colspan="1">2.03</td>
<td align="left" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Comorbidity</td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Hypertension</td>
<td align="left" rowspan="1" colspan="1">4446</td>
<td align="left" rowspan="1" colspan="1">(83.89)</td>
<td align="left" rowspan="1" colspan="1">1518</td>
<td align="left" rowspan="1" colspan="1">(84.99)</td>
<td align="left" rowspan="1" colspan="1">685</td>
<td align="left" rowspan="1" colspan="1">(81.16)</td>
<td align="left" rowspan="1" colspan="1">2243</td>
<td align="left" rowspan="1" colspan="1">(84.01)</td>
<td align="left" rowspan="1" colspan="1">0.04</td>
<td align="left" rowspan="1" colspan="1">83.88</td>
<td align="left" rowspan="1" colspan="1">84.10</td>
<td align="left" rowspan="1" colspan="1">83.82</td>
<td align="left" rowspan="1" colspan="1">0.98</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Diabetes mellitus</td>
<td align="left" rowspan="1" colspan="1">3791</td>
<td align="left" rowspan="1" colspan="1">(71.53)</td>
<td align="left" rowspan="1" colspan="1">1278</td>
<td align="left" rowspan="1" colspan="1">(71.56)</td>
<td align="left" rowspan="1" colspan="1">583</td>
<td align="left" rowspan="1" colspan="1">(69.08)</td>
<td align="left" rowspan="1" colspan="1">1930</td>
<td align="left" rowspan="1" colspan="1">(72.28)</td>
<td align="left" rowspan="1" colspan="1">0.20</td>
<td align="left" rowspan="1" colspan="1">71.25</td>
<td align="left" rowspan="1" colspan="1">71.10</td>
<td align="left" rowspan="1" colspan="1">71.92</td>
<td align="left" rowspan="1" colspan="1">0.85</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Dyslipidemia</td>
<td align="left" rowspan="1" colspan="1">2270</td>
<td align="left" rowspan="1" colspan="1">(42.83)</td>
<td align="left" rowspan="1" colspan="1">776</td>
<td align="left" rowspan="1" colspan="1">(43.45)</td>
<td align="left" rowspan="1" colspan="1">322</td>
<td align="left" rowspan="1" colspan="1">(38.15)</td>
<td align="left" rowspan="1" colspan="1">1172</td>
<td align="left" rowspan="1" colspan="1">(43.90)</td>
<td align="left" rowspan="1" colspan="1">0.01</td>
<td align="left" rowspan="1" colspan="1">43.03</td>
<td align="left" rowspan="1" colspan="1">42.83</td>
<td align="left" rowspan="1" colspan="1">42.70</td>
<td align="left" rowspan="1" colspan="1">0.98</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Coronary artery disease</td>
<td align="left" rowspan="1" colspan="1">2407</td>
<td align="left" rowspan="1" colspan="1">(45.42)</td>
<td align="left" rowspan="1" colspan="1">935</td>
<td align="left" rowspan="1" colspan="1">(52.35)</td>
<td align="left" rowspan="1" colspan="1">250</td>
<td align="left" rowspan="1" colspan="1">(29.62)</td>
<td align="left" rowspan="1" colspan="1">1222</td>
<td align="left" rowspan="1" colspan="1">(45.77)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.01</td>
<td align="left" rowspan="1" colspan="1">45.44</td>
<td align="left" rowspan="1" colspan="1">45.14</td>
<td align="left" rowspan="1" colspan="1">45.41</td>
<td align="left" rowspan="1" colspan="1">0.99</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Chronic kidney disease</td>
<td align="left" rowspan="1" colspan="1">2439</td>
<td align="left" rowspan="1" colspan="1">(46.02)</td>
<td align="left" rowspan="1" colspan="1">797</td>
<td align="left" rowspan="1" colspan="1">(44.62)</td>
<td align="left" rowspan="1" colspan="1">400</td>
<td align="left" rowspan="1" colspan="1">(47.39)</td>
<td align="left" rowspan="1" colspan="1">1242</td>
<td align="left" rowspan="1" colspan="1">(46.52)</td>
<td align="left" rowspan="1" colspan="1">0.32</td>
<td align="left" rowspan="1" colspan="1">46.50</td>
<td align="left" rowspan="1" colspan="1">45.12</td>
<td align="left" rowspan="1" colspan="1">46.10</td>
<td align="left" rowspan="1" colspan="1">0.83</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">End stage renal disease</td>
<td align="left" rowspan="1" colspan="1">56</td>
<td align="left" rowspan="1" colspan="1">(1.06)</td>
<td align="left" rowspan="1" colspan="1">19</td>
<td align="left" rowspan="1" colspan="1">(1.06)</td>
<td align="left" rowspan="1" colspan="1">14</td>
<td align="left" rowspan="1" colspan="1">(1.66)</td>
<td align="left" rowspan="1" colspan="1">23</td>
<td align="left" rowspan="1" colspan="1">(0.86)</td>
<td align="left" rowspan="1" colspan="1">0.14</td>
<td align="left" rowspan="1" colspan="1">1.11</td>
<td align="left" rowspan="1" colspan="1">1.14</td>
<td align="left" rowspan="1" colspan="1">1.03</td>
<td align="left" rowspan="1" colspan="1">0.95</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Medications</td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">*Rivaroxaban 2.5 mg</td>
<td align="left" rowspan="1" colspan="1">11</td>
<td align="left" rowspan="1" colspan="1">(0.21)</td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1">–</td>
<td align="left" rowspan="1" colspan="1">–</td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1"></td>
<td align="left" rowspan="1" colspan="1">–</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Statin</td>
<td align="left" rowspan="1" colspan="1">2728</td>
<td align="left" rowspan="1" colspan="1">(51.47)</td>
<td align="left" rowspan="1" colspan="1">971</td>
<td align="left" rowspan="1" colspan="1">(54.37)</td>
<td align="left" rowspan="1" colspan="1">333</td>
<td align="left" rowspan="1" colspan="1">(39.45)</td>
<td align="left" rowspan="1" colspan="1">1424</td>
<td align="left" rowspan="1" colspan="1">(53.33)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.01</td>
<td align="left" rowspan="1" colspan="1">51.32</td>
<td align="left" rowspan="1" colspan="1">51.11</td>
<td align="left" rowspan="1" colspan="1">51.40</td>
<td align="left" rowspan="1" colspan="1">0.99</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Calcium channel blocker</td>
<td align="left" rowspan="1" colspan="1">1415</td>
<td align="left" rowspan="1" colspan="1">(26.70)</td>
<td align="left" rowspan="1" colspan="1">483</td>
<td align="left" rowspan="1" colspan="1">(27.04)</td>
<td align="left" rowspan="1" colspan="1">222</td>
<td align="left" rowspan="1" colspan="1">(26.3)</td>
<td align="left" rowspan="1" colspan="1">710</td>
<td align="left" rowspan="1" colspan="1">(26.59)</td>
<td align="left" rowspan="1" colspan="1">0.91</td>
<td align="left" rowspan="1" colspan="1">27.43</td>
<td align="left" rowspan="1" colspan="1">26.62</td>
<td align="left" rowspan="1" colspan="1">26.45</td>
<td align="left" rowspan="1" colspan="1">0.77</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">Beta blocker</td>
<td align="left" rowspan="1" colspan="1">2287</td>
<td align="left" rowspan="1" colspan="1">(43.15)</td>
<td align="left" rowspan="1" colspan="1">752</td>
<td align="left" rowspan="1" colspan="1">(42.11)</td>
<td align="left" rowspan="1" colspan="1">312</td>
<td align="left" rowspan="1" colspan="1">(36.97)</td>
<td align="left" rowspan="1" colspan="1">1223</td>
<td align="left" rowspan="1" colspan="1">(45.81)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.01</td>
<td align="left" rowspan="1" colspan="1">43.25</td>
<td align="left" rowspan="1" colspan="1">43.66</td>
<td align="left" rowspan="1" colspan="1">43.20</td>
<td align="left" rowspan="1" colspan="1">0.98</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">ACEi/ARB</td>
<td align="left" rowspan="1" colspan="1">2677</td>
<td align="left" rowspan="1" colspan="1">(50.51)</td>
<td align="left" rowspan="1" colspan="1">995</td>
<td align="left" rowspan="1" colspan="1">(55.71)</td>
<td align="left" rowspan="1" colspan="1">368</td>
<td align="left" rowspan="1" colspan="1">(43.60)</td>
<td align="left" rowspan="1" colspan="1">1314</td>
<td align="left" rowspan="1" colspan="1">(49.21)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.01</td>
<td align="left" rowspan="1" colspan="1">50.65</td>
<td align="left" rowspan="1" colspan="1">50.46</td>
<td align="left" rowspan="1" colspan="1">50.46</td>
<td align="left" rowspan="1" colspan="1">0.99</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">SGLT2 inhibitor</td>
<td align="left" rowspan="1" colspan="1">187</td>
<td align="left" rowspan="1" colspan="1">(3.53)</td>
<td align="left" rowspan="1" colspan="1">82</td>
<td align="left" rowspan="1" colspan="1">(4.59)</td>
<td align="left" rowspan="1" colspan="1">18</td>
<td align="left" rowspan="1" colspan="1">(2.13)</td>
<td align="left" rowspan="1" colspan="1">87</td>
<td align="left" rowspan="1" colspan="1">(3.26)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.01</td>
<td align="left" rowspan="1" colspan="1">3.60</td>
<td align="left" rowspan="1" colspan="1">3.41</td>
<td align="left" rowspan="1" colspan="1">3.58</td>
<td align="left" rowspan="1" colspan="1">0.98</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">GLP-1RA</td>
<td align="left" rowspan="1" colspan="1">69</td>
<td align="left" rowspan="1" colspan="1">(1.30)</td>
<td align="left" rowspan="1" colspan="1">21</td>
<td align="left" rowspan="1" colspan="1">(1.18)</td>
<td align="left" rowspan="1" colspan="1">11</td>
<td align="left" rowspan="1" colspan="1">(1.30)</td>
<td align="left" rowspan="1" colspan="1">37</td>
<td align="left" rowspan="1" colspan="1">(1.39)</td>
<td align="left" rowspan="1" colspan="1">0.83</td>
<td align="left" rowspan="1" colspan="1">1.12</td>
<td align="left" rowspan="1" colspan="1">1.61</td>
<td align="left" rowspan="1" colspan="1">1.39</td>
<td align="left" rowspan="1" colspan="1">0.60</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/pone.0330434.t001/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="t001fn001"><p>Abbreviations: ACEi: Angiotensin-Converting Enzyme Inhibitor; ARB: Angiotensin II Receptor Blocker; GLP-1RA: Glucagon-Like Peptide-1 Receptor Agonist; PTA: Percutaneous Transluminal Angioplasty; SGLT2 Inhibitor: Sodium-Glucose Cotransporter 2 Inhibitor.</p></div>
<div class="fn" id="t001fn002"><p>* Because the case number of thrombocytopenia was too small in one of the groups, the distribution of case number between groups was not allowed to be presented by the Taiwan Ministry of Health and Welfare.</p></div>
</div></section><p>To account for differences in baseline characteristics—such as sex, number of PTA procedures, comorbidities, and concomitant medications—we applied IPTW. After adjustment, there were no significant differences among the three treatment groups (<a href="#pone.0330434.t001" class="usa-link">Table 1</a>).</p></section><section id="sec013"><h3 class="pmc_sec_title">Clinical outcomes</h3>
<p>The mean follow-up time was 2.68 years. During this period, the overall incidence rates of MACE, MALE, and composite bleeding were 16.3%, 22.9%, and 13.8%, respectively. When comparing cilostazol monotherapy with aspirin or clopidogrel monotherapy, there were no statistically significant differences in the incidence of MACE (adjusted hazard ratio (aHR), 0.84; 95% CI, 0.68–1.03; <em>p</em> = 0.09) or MALE (aHR, 0.84; 95% CI, 0.70–1.01; <em>p</em> = 0.06, <a href="#pone.0330434.t002" class="usa-link">Table 2</a>. Among the secondary endpoints, cilostazol monotherapy was associated with a significantly lower risk of repeat PTA (aHR, 0.80; 95% CI, 0.66–0.98; <em>p</em> = 0.03). While there were no significant differences in the overall incidence of composite bleeding across groups, gastrointestinal bleeding appeared numerically lower in the cilostazol monotherapy group (aHR, 0.76; 95% CI, 0.57–1.01; <em>p</em> = 0.05). These findings suggest that cilostazol monotherapy may offer comparable clinical outcomes relative to aspirin or clopidogrel monotherapy in routine clinical practice.</p>
<section class="tw xbox font-sm" id="pone.0330434.t002"><h4 class="obj_head">Table 2. Outcomes of LEAD patients received cilostazol and/or antiplatelet.</h4>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
<col align="left" valign="middle" span="1">
</colgroup>
<thead>
<tr>
<th align="left" rowspan="2" colspan="1"></th>
<th align="left" colspan="2" rowspan="2">Total (N = 5300)</th>
<th align="left" colspan="2" rowspan="2">Aspirin or Plavix users. (ref.) (N = 1786)</th>
<th align="left" colspan="2" rowspan="2">Cilostazol users (N = 844)</th>
<th align="left" colspan="2" rowspan="2">Aspirin+Cilostazol or Plavix+Cilostazol (N = 2670)</th>
<th align="left" rowspan="1" colspan="1"></th>
<th align="left" colspan="2" rowspan="1">*Non IPTW</th>
<th align="left" colspan="2" rowspan="1">IPTW</th>
</tr>
<tr>
<th align="left" rowspan="1" colspan="1"></th>
<th align="left" rowspan="1" colspan="1">Adjusted HR (95% CI)</th>
<th align="left" rowspan="1" colspan="1">p value</th>
<th align="left" rowspan="1" colspan="1">HR (95% CI)</th>
<th align="left" rowspan="1" colspan="1">p value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="2" colspan="1">Death</td>
<td align="left" rowspan="2" colspan="1">1814</td>
<td align="left" rowspan="2" colspan="1">(34.23)</td>
<td align="left" rowspan="2" colspan="1">602</td>
<td align="left" rowspan="2" colspan="1">(33.71)</td>
<td align="left" rowspan="2" colspan="1">312</td>
<td align="left" rowspan="2" colspan="1">(36.97)</td>
<td align="left" rowspan="2" colspan="1">900</td>
<td align="left" rowspan="2" colspan="1">(33.71)</td>
<td align="left" rowspan="1" colspan="1">C</td>
<td align="left" rowspan="1" colspan="1">0.96 (0.84-1.10)</td>
<td align="left" rowspan="1" colspan="1">0.56</td>
<td align="left" rowspan="1" colspan="1">0.88 (0.76-1.01)</td>
<td align="left" rowspan="1" colspan="1">0.07</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">A + P</td>
<td align="left" rowspan="1" colspan="1">0.91 (0.82-1.01)</td>
<td align="left" rowspan="1" colspan="1">0.08</td>
<td align="left" rowspan="1" colspan="1">0.90 (0.81-0.99)</td>
<td align="left" rowspan="1" colspan="1">0.04</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">MACEs</td>
<td align="left" rowspan="2" colspan="1">863</td>
<td align="left" rowspan="2" colspan="1">(16.28)</td>
<td align="left" rowspan="2" colspan="1">302</td>
<td align="left" rowspan="2" colspan="1">(16.91)</td>
<td align="left" rowspan="2" colspan="1">138</td>
<td align="left" rowspan="2" colspan="1">(16.35)</td>
<td align="left" rowspan="2" colspan="1">423</td>
<td align="left" rowspan="2" colspan="1">(15.84)</td>
<td align="left" rowspan="1" colspan="1">C</td>
<td align="left" rowspan="1" colspan="1">0.90 (0.73-1.10)</td>
<td align="left" rowspan="1" colspan="1">0.30</td>
<td align="left" rowspan="1" colspan="1">0.84 (0.68-1.03)</td>
<td align="left" rowspan="1" colspan="1">0.09</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">A + P</td>
<td align="left" rowspan="1" colspan="1">0.86 (0.74-1.00)</td>
<td align="left" rowspan="1" colspan="1">0.05</td>
<td align="left" rowspan="1" colspan="1">0.87 (0.75-1.00)</td>
<td align="left" rowspan="1" colspan="1">0.06</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">Cardiovascular death</td>
<td align="left" rowspan="2" colspan="1">377</td>
<td align="left" rowspan="2" colspan="1">(7.11)</td>
<td align="left" rowspan="2" colspan="1">127</td>
<td align="left" rowspan="2" colspan="1">(7.11)</td>
<td align="left" rowspan="2" colspan="1">68</td>
<td align="left" rowspan="2" colspan="1">(8.06)</td>
<td align="left" rowspan="2" colspan="1">182</td>
<td align="left" rowspan="2" colspan="1">(6.82)</td>
<td align="left" rowspan="1" colspan="1">C</td>
<td align="left" rowspan="1" colspan="1">1.00 (0.74-1.35)</td>
<td align="left" rowspan="1" colspan="1">0.98</td>
<td align="left" rowspan="1" colspan="1">0.89 (0.65-1.20)</td>
<td align="left" rowspan="1" colspan="1">0.43</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">A + P</td>
<td align="left" rowspan="1" colspan="1">0.87 (0.70-1.10)</td>
<td align="left" rowspan="1" colspan="1">0.25</td>
<td align="left" rowspan="1" colspan="1">0.87 (0.70-1.09)</td>
<td align="left" rowspan="1" colspan="1">0.22</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">Non-fatal MI</td>
<td align="left" rowspan="2" colspan="1">382</td>
<td align="left" rowspan="2" colspan="1">(7.21)</td>
<td align="left" rowspan="2" colspan="1">141</td>
<td align="left" rowspan="2" colspan="1">(7.89)</td>
<td align="left" rowspan="2" colspan="1">55</td>
<td align="left" rowspan="2" colspan="1">(6.52)</td>
<td align="left" rowspan="2" colspan="1">186</td>
<td align="left" rowspan="2" colspan="1">(6.97)</td>
<td align="left" rowspan="1" colspan="1">C</td>
<td align="left" rowspan="1" colspan="1">0.83 (0.60-1.14)</td>
<td align="left" rowspan="1" colspan="1">0.25</td>
<td align="left" rowspan="1" colspan="1">0.80 (0.58-1.09)</td>
<td align="left" rowspan="1" colspan="1">0.15</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">A + P</td>
<td align="left" rowspan="1" colspan="1">0.82 (0.66-1.03)</td>
<td align="left" rowspan="1" colspan="1">0.08</td>
<td align="left" rowspan="1" colspan="1">0.85 (0.68-1.06)</td>
<td align="left" rowspan="1" colspan="1">0.14</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">Ischemic stroke/TIA</td>
<td align="left" rowspan="2" colspan="1">275</td>
<td align="left" rowspan="2" colspan="1">(5.19)</td>
<td align="left" rowspan="2" colspan="1">104</td>
<td align="left" rowspan="2" colspan="1">(5.82)</td>
<td align="left" rowspan="2" colspan="1">38</td>
<td align="left" rowspan="2" colspan="1">(4.50)</td>
<td align="left" rowspan="2" colspan="1">133</td>
<td align="left" rowspan="2" colspan="1">(4.98)</td>
<td align="left" rowspan="1" colspan="1">C</td>
<td align="left" rowspan="1" colspan="1">0.72 (0.49-1.05)</td>
<td align="left" rowspan="1" colspan="1">0.09</td>
<td align="left" rowspan="1" colspan="1">0.74 (0.51-1.06)</td>
<td align="left" rowspan="1" colspan="1">0.10</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">A + P</td>
<td align="left" rowspan="1" colspan="1">0.81 (0.62-1.04)</td>
<td align="left" rowspan="1" colspan="1">0.10</td>
<td align="left" rowspan="1" colspan="1">0.78 (0.60-1.00)</td>
<td align="left" rowspan="1" colspan="1">0.05</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">MALEs</td>
<td align="left" rowspan="2" colspan="1">1213</td>
<td align="left" rowspan="2" colspan="1">(22.89)</td>
<td align="left" rowspan="2" colspan="1">383</td>
<td align="left" rowspan="2" colspan="1">(21.44)</td>
<td align="left" rowspan="2" colspan="1">163</td>
<td align="left" rowspan="2" colspan="1">(19.31)</td>
<td align="left" rowspan="2" colspan="1">667</td>
<td align="left" rowspan="2" colspan="1">(24.98)</td>
<td align="left" rowspan="1" colspan="1">C</td>
<td align="left" rowspan="1" colspan="1">0.84 (0.70-1.02)</td>
<td align="left" rowspan="1" colspan="1">0.07</td>
<td align="left" rowspan="1" colspan="1">0.84 (0.70-1.01)</td>
<td align="left" rowspan="1" colspan="1">0.06</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">A + P</td>
<td align="left" rowspan="1" colspan="1">1.10 (0.97-1.25)</td>
<td align="left" rowspan="1" colspan="1">0.13</td>
<td align="left" rowspan="1" colspan="1">1.08 (0.96-1.23)</td>
<td align="left" rowspan="1" colspan="1">0.21</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">Angioplasty for LEAD</td>
<td align="left" rowspan="2" colspan="1">1087</td>
<td align="left" rowspan="2" colspan="1">(20.51)</td>
<td align="left" rowspan="2" colspan="1">342</td>
<td align="left" rowspan="2" colspan="1">(19.15)</td>
<td align="left" rowspan="2" colspan="1">136</td>
<td align="left" rowspan="2" colspan="1">(16.11)</td>
<td align="left" rowspan="2" colspan="1">609</td>
<td align="left" rowspan="2" colspan="1">(22.81)</td>
<td align="left" rowspan="1" colspan="1">C</td>
<td align="left" rowspan="1" colspan="1">0.80 (0.65-0.98)</td>
<td align="left" rowspan="1" colspan="1">0.03</td>
<td align="left" rowspan="1" colspan="1">0.80 (0.66-0.98)</td>
<td align="left" rowspan="1" colspan="1">0.03</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">A + P</td>
<td align="left" rowspan="1" colspan="1">1.14 (0.99-1.30)</td>
<td align="left" rowspan="1" colspan="1">0.06</td>
<td align="left" rowspan="1" colspan="1">1.11 (0.97-1.26)</td>
<td align="left" rowspan="1" colspan="1">0.12</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">Amputation</td>
<td align="left" rowspan="2" colspan="1">325</td>
<td align="left" rowspan="2" colspan="1">(6.13)</td>
<td align="left" rowspan="2" colspan="1">108</td>
<td align="left" rowspan="2" colspan="1">(6.05)</td>
<td align="left" rowspan="2" colspan="1">53</td>
<td align="left" rowspan="2" colspan="1">(6.28)</td>
<td align="left" rowspan="2" colspan="1">164</td>
<td align="left" rowspan="2" colspan="1">(6.14)</td>
<td align="left" rowspan="1" colspan="1">C</td>
<td align="left" rowspan="1" colspan="1">0.95 (0.68-1.32)</td>
<td align="left" rowspan="1" colspan="1">0.75</td>
<td align="left" rowspan="1" colspan="1">0.89 (0.64-1.25)</td>
<td align="left" rowspan="1" colspan="1">0.50</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">A + P</td>
<td align="left" rowspan="1" colspan="1">0.95 (0.74-1.21)</td>
<td align="left" rowspan="1" colspan="1">0.66</td>
<td align="left" rowspan="1" colspan="1">0.96 (0.75-1.21)</td>
<td align="left" rowspan="1" colspan="1">0.71</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">Composite bleeding</td>
<td align="left" rowspan="2" colspan="1">732</td>
<td align="left" rowspan="2" colspan="1">(13.81)</td>
<td align="left" rowspan="2" colspan="1">240</td>
<td align="left" rowspan="2" colspan="1">(13.44)</td>
<td align="left" rowspan="2" colspan="1">115</td>
<td align="left" rowspan="2" colspan="1">(13.63)</td>
<td align="left" rowspan="2" colspan="1">377</td>
<td align="left" rowspan="2" colspan="1">(14.12)</td>
<td align="left" rowspan="1" colspan="1">C</td>
<td align="left" rowspan="1" colspan="1">0.90 (0.72-1.13)</td>
<td align="left" rowspan="1" colspan="1">0.36</td>
<td align="left" rowspan="1" colspan="1">0.88 (0.71-1.10)</td>
<td align="left" rowspan="1" colspan="1">0.26</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">A + P</td>
<td align="left" rowspan="1" colspan="1">0.96 (0.81-1.13)</td>
<td align="left" rowspan="1" colspan="1">0.61</td>
<td align="left" rowspan="1" colspan="1">0.94 (0.81-1.11)</td>
<td align="left" rowspan="1" colspan="1">0.48</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">Hemorrhagic stroke</td>
<td align="left" rowspan="2" colspan="1">45</td>
<td align="left" rowspan="2" colspan="1">(0.85)</td>
<td align="left" rowspan="2" colspan="1">17</td>
<td align="left" rowspan="2" colspan="1">(0.95)</td>
<td align="left" rowspan="2" colspan="1">6</td>
<td align="left" rowspan="2" colspan="1">(0.71)</td>
<td align="left" rowspan="2" colspan="1">22</td>
<td align="left" rowspan="2" colspan="1">(0.82)</td>
<td align="left" rowspan="1" colspan="1">C</td>
<td align="left" rowspan="1" colspan="1">0.66 (0.25-1.69)</td>
<td align="left" rowspan="1" colspan="1">0.38</td>
<td align="left" rowspan="1" colspan="1">0.60 (0.24-1.53)</td>
<td align="left" rowspan="1" colspan="1">0.28</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">A + P</td>
<td align="left" rowspan="1" colspan="1">0.83 (0.44-1.57)</td>
<td align="left" rowspan="1" colspan="1">0.57</td>
<td align="left" rowspan="1" colspan="1">0.77 (0.42-1.42)</td>
<td align="left" rowspan="1" colspan="1">0.40</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">Gastrointestinal bleeding</td>
<td align="left" rowspan="2" colspan="1">470</td>
<td align="left" rowspan="2" colspan="1">(8.87)</td>
<td align="left" rowspan="2" colspan="1">160</td>
<td align="left" rowspan="2" colspan="1">(8.96)</td>
<td align="left" rowspan="2" colspan="1">65</td>
<td align="left" rowspan="2" colspan="1">(7.7)</td>
<td align="left" rowspan="2" colspan="1">245</td>
<td align="left" rowspan="2" colspan="1">(9.18)</td>
<td align="left" rowspan="1" colspan="1">C</td>
<td align="left" rowspan="1" colspan="1">0.76 (0.57-1.02)</td>
<td align="left" rowspan="1" colspan="1">0.07</td>
<td align="left" rowspan="1" colspan="1">0.76 (0.57-1.01)</td>
<td align="left" rowspan="1" colspan="1">0.05</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">A + P</td>
<td align="left" rowspan="1" colspan="1">0.93 (0.76-1.14)</td>
<td align="left" rowspan="1" colspan="1">0.47</td>
<td align="left" rowspan="1" colspan="1">0.91 (0.75-1.10)</td>
<td align="left" rowspan="1" colspan="1">0.33</td>
</tr>
<tr>
<td align="left" rowspan="2" colspan="1">Other site bleeding</td>
<td align="left" rowspan="2" colspan="1">331</td>
<td align="left" rowspan="2" colspan="1">(6.25)</td>
<td align="left" rowspan="2" colspan="1">101</td>
<td align="left" rowspan="2" colspan="1">(5.66)</td>
<td align="left" rowspan="2" colspan="1">62</td>
<td align="left" rowspan="2" colspan="1">(7.35)</td>
<td align="left" rowspan="2" colspan="1">168</td>
<td align="left" rowspan="2" colspan="1">(6.29)</td>
<td align="left" rowspan="1" colspan="1">C</td>
<td align="left" rowspan="1" colspan="1">1.16 (0.84-1.61)</td>
<td align="left" rowspan="1" colspan="1">0.36</td>
<td align="left" rowspan="1" colspan="1">1.12 (0.81-1.53)</td>
<td align="left" rowspan="1" colspan="1">0.50</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1">A + P</td>
<td align="left" rowspan="1" colspan="1">1.02 (0.79-1.31)</td>
<td align="left" rowspan="1" colspan="1">0.89</td>
<td align="left" rowspan="1" colspan="1">1.00 (0.79-1.28)</td>
<td align="left" rowspan="1" colspan="1">0.99</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/pone.0330434.t002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p">
<div class="fn" id="t002fn001"><p>Abbreviations: LEAD: CI, confidence interval; HR, hazard ratio; Lower Extremity Arterial Disease; MACE: Major Adverse Cardiovascular Events; MALE: Major Adverse Limb Events; MI: Myocardial Infarction; TIA: Transient Ischemic Attack.</p></div>
<div class="fn" id="t002fn002"><p>* This model represents the pre-IPTW analysis, with adjustment for age, gender, times of PTA, comorbidity (hypertension, dyslipidemia, coronary artery disease), and medications (statin, beta blocker, ACEi/ARB, SGLT2 inhibitor).</p></div>
</div></section><p>In comparisons between aspirin or clopidogrel monotherapy and combination therapy with cilostazol, there were no statistically significant differences in the incidence of MACE (aHR, 0.87; 95% CI, 0.75–1.00; <em>p</em> = 0.06), MALE (aHR, 1.11; 95% CI, 0.97–1.26; <em>p</em> = 0.12), or composite bleeding (aHR, 0.94; 95% CI, 0.81–1.11; <em>p</em> = 0.26). The confidence interval for MACE approached the threshold for statistical significance.</p></section><section id="sec014"><h3 class="pmc_sec_title">Subgroup analyses</h3>
<p>Subgroup analyses were performed based on key baseline characteristics, including age, sex, times of PTA, diabetes, hypertension, dyslipidemia, coronary artery disease, chronic kidney disease, and end stage renal disease (<a href="#pone.0330434.g002" class="usa-link">Fig 2</a> and <a href="#pone.0330434.s002" class="usa-link">Supplemental Fig 2</a>). Overall, the treatment effects were generally consistent across subgroups. The direction and magnitude of treatment effects remained similar in most strata, suggesting broadly consistent results across the study population.</p>
<figure class="fig xbox font-sm" id="pone.0330434.g002"><h4 class="obj_head">Fig 2. Subgroup analysis of major adverse cardiovascular events and major adverse limb events between cilostazol users and aspirin or Plavix users.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12370041_pone.0330434.g002.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/20bc/12370041/420ad29a845d/pone.0330434.g002.jpg" loading="lazy" height="321" width="750" alt="Fig 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/pone.0330434.g002/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure></section></section><section id="sec015"><h2 class="pmc_sec_title">Discussion</h2>
<p>In this real-world cohort of stable LEAD patients who underwent PTA, cilostazol therapy was associated with clinical outcomes comparable to those observed with aspirin or clopidogrel therapy. No statistically significant differences were noted in the incidence of MACE, MALE, or composite bleeding. In secondary analyses, cilostazol was associated with a significantly lower rate of repeat angioplasty, suggesting a potential benefit in reducing restenosis or recurrent limb ischemia.</p>
<p>LEAD remains a condition with a notably high mortality rate, surpassing that CAD and stroke. [<a href="#pone.0330434.ref012" class="usa-link" aria-describedby="pone.0330434.ref012">12</a>,<a href="#pone.0330434.ref013" class="usa-link" aria-describedby="pone.0330434.ref013">13</a>] A large cohort study reported event rates for all-cause mortality and MACE in LEAD patients to be approximately 113 and 71 per 1,000 person-years, respectively. In our cohort of 17,993 patients undergoing PTA—likely representing a population with more advanced disease—we observed a 21% one-year mortality rate and a 22% incidence of MACE or MALE. These strikingly high complication rates underscore the critical need for comprehensive care strategies that extend beyond revascularization alone. Early detection and the implementation of guideline-directed medical therapy are crucial cornerstones in managing LEAD patients. These findings further emphasize the importance of evaluating the potential benefits of individual pharmacologic therapies in improving outcomes in this high-risk population.</p>
<p>Cilostazol has been shown to exert multiple pleiotropic effects that may offer meaningful clinical benefits to patients with LEAD. Beyond its primary pharmacologic actions, inhibition of platelet aggregation and induction of vasodilation, cilostazol has demonstrated the ability to protect against apoptotic cell death, [<a href="#pone.0330434.ref014" class="usa-link" aria-describedby="pone.0330434.ref014">14</a>] anti-inflammation, [<a href="#pone.0330434.ref015" class="usa-link" aria-describedby="pone.0330434.ref015">15</a>] promote angiogenesis, and enhance endothelial function [<a href="#pone.0330434.ref006" class="usa-link" aria-describedby="pone.0330434.ref006">6</a>–<a href="#pone.0330434.ref008" class="usa-link" aria-describedby="pone.0330434.ref008">8</a>]. Clinically, these biological effects translate into improved patient outcomes, including reduction in claudication symptoms, [<a href="#pone.0330434.ref016" class="usa-link" aria-describedby="pone.0330434.ref016">16</a>] increase walking distance, [<a href="#pone.0330434.ref017" class="usa-link" aria-describedby="pone.0330434.ref017">17</a>] and a lower risk of restenosis, re-occlusion, target lesion revascularization, [<a href="#pone.0330434.ref018" class="usa-link" aria-describedby="pone.0330434.ref018">18</a>] and even amputation. [<a href="#pone.0330434.ref019" class="usa-link" aria-describedby="pone.0330434.ref019">19</a>] Our findings complement and expand upon previous evidence by showing, in a real-world cohort, that cilostazol monotherapy was associated with a significantly lower rate of repeat PTA procedures compared to aspirin or clopidogrel monotherapy, without increasing the risk of MACE or bleeding. Although real-world data are inherently prone to selection bias, it is worth noting that cilostazol is often prescribed to patients with more pronounced symptoms. The observed reduction in MALE events may therefore reflect cilostazol’s clinical effectiveness. Conversely, this same bias may partially explain why combination therapy with cilostazol and aspirin or clopidogrel did not show a statistically significant benefit over single-agent therapy, as those patients might have had more advanced disease at baseline.</p>
<p>In addition to its benefits in reducing MALE, cilostazol has also been evaluated for its potential role in lowering the risk of MACE. [<a href="#pone.0330434.ref020" class="usa-link" aria-describedby="pone.0330434.ref020">20</a>] A randomized controlled trial in high-risk cardiovascular patients reported a hazard ratio of 0.67 for MACE in the cilostazol group, suggesting a possible protective effect, particularly in subgroups with diabetes or prior percutaneous coronary intervention. [<a href="#pone.0330434.ref010" class="usa-link" aria-describedby="pone.0330434.ref010">10</a>] Similarly, a meta-analysis of 15 trials demonstrated a significant reduction in MACE risk (RR = 0.67; 95% CI, 0.56–0.81), although no difference in all-cause mortality was observed. [<a href="#pone.0330434.ref009" class="usa-link" aria-describedby="pone.0330434.ref009">9</a>] In hemodialysis patients with LEAD, cilostazol was associated with improved 10-year MACE-free survival (HR 0.57; 95% CI, 0.41–0.79). [<a href="#pone.0330434.ref021" class="usa-link" aria-describedby="pone.0330434.ref021">21</a>] In our real-world dataset, cilostazol monotherapy showed no significant difference in MACE risk compared to aspirin or clopidogrel. However, dual therapy combining cilostazol with either aspirin or clopidogrel yielded a hazard ratio for MACE (HR 0.87; 95% CI, 0.75–1.00) and stroke (HR 0.78; 95% CI, 0.60–1.00) that were numerically lower, though these did not meet the threshold for statistical significance. Subgroup analyses revealed generally consistent effects across various patient characteristics, further supporting the potential cardiovascular benefits of cilostazol in selected populations.</p>
<p>Several limitations should be considered when interpreting our findings. First, although we employed robust statistical adjustments using IPTW, the potential for residual confounding due to unmeasured variables—such as Rutherford classification, lesion severity, ankle-brachial index, degree of calcification, and lifestyle factors—cannot be entirely excluded. Second, as with all observational studies, the possibility of other uncontrolled sources of bias and confounding remains, warranting cautious interpretation of the results. Third, the data reflect clinical practice patterns between 2013 and 2020, a period when the adoption of newer cardiometabolic therapies—such as SGLT2 inhibitors, GLP-1 receptor agonists, and low-dose rivaroxaban (2.5 mg)—was limited. Therefore, the generalizability of our findings to more contemporary treatment paradigms may be constrained. Fourth, the use of a landmark design mitigated immortal time bias and strengthened internal validity, but may limit generalizability to patients with early post-PTA events.</p>
<p>In conclusion, this nationwide real-world analysis suggests that cilostazol monotherapy provides clinical outcomes and safety comparable to conventional antiplatelet therapy in stable LEAD patients following PTA. In addition, cilostazol was associated with a reduced need for repeat revascularization. These findings support its consideration as a viable therapeutic option in routine practice. Further randomized trials or prospective studies are warranted to confirm these results and clarify cilostazol’s role within the broader context of modern LEAD management.</p></section><section id="sec016"><h2 class="pmc_sec_title">Supporting information</h2>
<section class="sm xbox font-sm" id="pone.0330434.s001"><div class="caption p">
<span>Supplemental Fig 1. Schematic diagram of the data collection timeline. (LEAD: lower extremities artery disease; MACE: major adverse cardiovascular events; MALE: major adverse limb events; N: number of participants; NOAC: Novel oral anticoagulants; PTA: percutaneous transluminal angioplasty).</span><p>(TIF)</p>
</div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12370041/bin/pone.0330434.s001.tif" data-ga-action="click_feat_suppl" class="usa-link">pone.0330434.s001.tif</a><sup> (62.7KB, tif) </sup>
</div></div></section><section class="sm xbox font-sm" id="pone.0330434.s002"><div class="caption p">
<span>Supplemental Fig 2. Subgroup analysis of major adverse cardiovascular events and major adverse limb events between cilostazol plus aspirin or Plavix users and aspirin or Plavix users.</span><p>(TIF)</p>
</div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12370041/bin/pone.0330434.s002.tif" data-ga-action="click_feat_suppl" class="usa-link">pone.0330434.s002.tif</a><sup> (366.6KB, tif) </sup>
</div></div></section><section class="sm xbox font-sm" id="pone.0330434.s003"><div class="caption p">
<span>S1 Table. Supplemental table 1. ICD-9 and ICD-10 codes.</span><p>(DOCX)</p>
</div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12370041/bin/pone.0330434.s003.docx" data-ga-action="click_feat_suppl" class="usa-link">pone.0330434.s003.docx</a><sup> (17KB, docx) </sup>
</div></div></section></section><section id="notes1"><h2 class="pmc_sec_title">Data Availability</h2>
<p>The minimal data set required to replicate the findings has been provided via this manuscript's <a href="#sec016" class="usa-link">Supporting Information</a> files. The original data derived from the National Health Insurance Research Database (NHIRD), Taiwan, are not publicly available due to legal and ethical restrictions. Access to these data requires formal application and approval by the Health and Welfare Data Science Center, Ministry of Health and Welfare, Taiwan. Requests for data access can be directed to the Health and Welfare Data Science Center via email (e.g., Mr. Wu at <span>stwu@mohw.gov.tw</span>) or through the official website: <a href="https://dep.mohw.gov.tw/DOS/np-2497-113.html" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://dep.mohw.gov.tw/DOS/np-2497-113.html</a>. The website provides detailed information on data application procedures and official contact points.</p></section><section id="funding-statement1" lang="en"><h2 class="pmc_sec_title">Funding Statement</h2>
<p>This work was supported by a grant from the Chung Shan Medical University Hospital (CSH-2025-D-002, Ting-Hsing Chao).</p></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="pone.0330434.ref001">
<span class="label">1.</span><cite>Callegari S, Romain G, Capuano I, Cleman J, Scierka L, Smolderen KG, et al. Association between guideline-directed medical therapy and reintervention risk following peripheral vascular interventions in patients with peripheral artery disease. Vasc Med. 2025;30(3):293–301. doi: 10.1177/1358863X251320347

</cite> [<a href="https://doi.org/10.1177/1358863X251320347" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39992181/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Vasc%20Med&amp;title=Association%20between%20guideline-directed%20medical%20therapy%20and%20reintervention%20risk%20following%20peripheral%20vascular%20interventions%20in%20patients%20with%20peripheral%20artery%20disease&amp;author=S%20Callegari&amp;author=G%20Romain&amp;author=I%20Capuano&amp;author=J%20Cleman&amp;author=L%20Scierka&amp;volume=30&amp;issue=3&amp;publication_year=2025&amp;pages=293-301&amp;pmid=39992181&amp;doi=10.1177/1358863X251320347&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pone.0330434.ref002">
<span class="label">2.</span><cite>Gornik HL, Aronow HD, Goodney PP, Arya S, Brewster LP, Byrd L, et al. 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2024;149(24):e1313–410. doi: 10.1161/CIR.0000000000001251

</cite> [<a href="https://doi.org/10.1161/CIR.0000000000001251" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38743805/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=2024%20ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS%20Guideline%20for%20the%20Management%20of%20Lower%20Extremity%20Peripheral%20Artery%20Disease:%20A%20Report%20of%20the%20American%20College%20of%20Cardiology/American%20Heart%20Association%20Joint%20Committee%20on%20Clinical%20Practice%20Guidelines&amp;author=HL%20Gornik&amp;author=HD%20Aronow&amp;author=PP%20Goodney&amp;author=S%20Arya&amp;author=LP%20Brewster&amp;volume=149&amp;issue=24&amp;publication_year=2024&amp;pmid=38743805&amp;doi=10.1161/CIR.0000000000001251&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pone.0330434.ref003">
<span class="label">3.</span><cite>Criqui MH, Matsushita K, Aboyans V, Hess CN, Hicks CW, Kwan TW, et al. Lower Extremity Peripheral Artery Disease: Contemporary Epidemiology, Management Gaps, and Future Directions: A Scientific Statement From the American Heart Association. Circulation. 2021;144(9):e171–91. doi: 10.1161/CIR.0000000000001005

</cite> [<a href="https://doi.org/10.1161/CIR.0000000000001005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9847212/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34315230/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Lower%20Extremity%20Peripheral%20Artery%20Disease:%20Contemporary%20Epidemiology,%20Management%20Gaps,%20and%20Future%20Directions:%20A%20Scientific%20Statement%20From%20the%20American%20Heart%20Association&amp;author=MH%20Criqui&amp;author=K%20Matsushita&amp;author=V%20Aboyans&amp;author=CN%20Hess&amp;author=CW%20Hicks&amp;volume=144&amp;issue=9&amp;publication_year=2021&amp;pmid=34315230&amp;doi=10.1161/CIR.0000000000001005&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pone.0330434.ref004">
<span class="label">4.</span><cite>Mazzolai L, Teixido-Tura G, Lanzi S, Boc V, Bossone E, Brodmann M, et al. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024;45(36):3538–700. doi: 10.1093/eurheartj/ehae179

</cite> [<a href="https://doi.org/10.1093/eurheartj/ehae179" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39210722/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20Heart%20J&amp;title=2024%20ESC%20Guidelines%20for%20the%20management%20of%20peripheral%20arterial%20and%20aortic%20diseases&amp;author=L%20Mazzolai&amp;author=G%20Teixido-Tura&amp;author=S%20Lanzi&amp;author=V%20Boc&amp;author=E%20Bossone&amp;volume=45&amp;issue=36&amp;publication_year=2024&amp;pages=3538-700&amp;pmid=39210722&amp;doi=10.1093/eurheartj/ehae179&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pone.0330434.ref005">
<span class="label">5.</span><cite>Cerecedo CD, Silva A, Alia VS, Vargas A, Garza A, El Shazly O, et al. Cilostazol after endovascular therapy for femoropopliteal peripheral arterial disease: A systematic review and meta-analysis. J Vasc Surg. 2025;81(3):767-774.e7. doi: 10.1016/j.jvs.2024.08.032

</cite> [<a href="https://doi.org/10.1016/j.jvs.2024.08.032" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39208919/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Vasc%20Surg&amp;title=Cilostazol%20after%20endovascular%20therapy%20for%20femoropopliteal%20peripheral%20arterial%20disease:%20A%20systematic%20review%20and%20meta-analysis&amp;author=CD%20Cerecedo&amp;author=A%20Silva&amp;author=VS%20Alia&amp;author=A%20Vargas&amp;author=A%20Garza&amp;volume=81&amp;issue=3&amp;publication_year=2025&amp;pmid=39208919&amp;doi=10.1016/j.jvs.2024.08.032&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pone.0330434.ref006">
<span class="label">6.</span><cite>Tseng S-Y, Chang H-Y, Li Y-H, Chao T-H. Effects of Cilostazol on Angiogenesis in Diabetes through Adiponectin/Adiponectin Receptors/Sirtuin1 Signaling Pathway. Int J Mol Sci. 2022;23(23):14839. doi: 10.3390/ijms232314839

</cite> [<a href="https://doi.org/10.3390/ijms232314839" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9739574/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36499166/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Mol%20Sci&amp;title=Effects%20of%20Cilostazol%20on%20Angiogenesis%20in%20Diabetes%20through%20Adiponectin/Adiponectin%20Receptors/Sirtuin1%20Signaling%20Pathway&amp;author=S-Y%20Tseng&amp;author=H-Y%20Chang&amp;author=Y-H%20Li&amp;author=T-H%20Chao&amp;volume=23&amp;issue=23&amp;publication_year=2022&amp;pages=14839&amp;pmid=36499166&amp;doi=10.3390/ijms232314839&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pone.0330434.ref007">
<span class="label">7.</span><cite>Tseng S-Y, Chao T-H, Li Y-H, Liu P-Y, Lee C-H, Cho C-L, et al. Cilostazol improves high glucose-induced impaired angiogenesis in human endothelial progenitor cells and vascular endothelial cells as well as enhances vasculoangiogenesis in hyperglycemic mice mediated by the adenosine monophosphate-activated protein kinase pathway. J Vasc Surg. 2016;63(4):1051-62.e3. doi: 10.1016/j.jvs.2014.10.103

</cite> [<a href="https://doi.org/10.1016/j.jvs.2014.10.103" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25595409/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Vasc%20Surg&amp;title=Cilostazol%20improves%20high%20glucose-induced%20impaired%20angiogenesis%20in%20human%20endothelial%20progenitor%20cells%20and%20vascular%20endothelial%20cells%20as%20well%20as%20enhances%20vasculoangiogenesis%20in%20hyperglycemic%20mice%20mediated%20by%20the%20adenosine%20monophosphate-activated%20protein%20kinase%20pathway&amp;author=S-Y%20Tseng&amp;author=T-H%20Chao&amp;author=Y-H%20Li&amp;author=P-Y%20Liu&amp;author=C-H%20Lee&amp;volume=63&amp;issue=4&amp;publication_year=2016&amp;pmid=25595409&amp;doi=10.1016/j.jvs.2014.10.103&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pone.0330434.ref008">
<span class="label">8.</span><cite>Chao T-H, Tseng S-Y, Chen I-C, Tsai Y-S, Huang Y-Y, Liu P-Y, et al. Cilostazol enhances mobilization and proliferation of endothelial progenitor cells and collateral formation by modifying vasculo-angiogenic biomarkers in peripheral arterial disease. Int J Cardiol. 2014;172(2):e371-4. doi: 10.1016/j.ijcard.2013.12.295

</cite> [<a href="https://doi.org/10.1016/j.ijcard.2013.12.295" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24439864/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Cardiol&amp;title=Cilostazol%20enhances%20mobilization%20and%20proliferation%20of%20endothelial%20progenitor%20cells%20and%20collateral%20formation%20by%20modifying%20vasculo-angiogenic%20biomarkers%20in%20peripheral%20arterial%20disease&amp;author=T-H%20Chao&amp;author=S-Y%20Tseng&amp;author=I-C%20Chen&amp;author=Y-S%20Tsai&amp;author=Y-Y%20Huang&amp;volume=172&amp;issue=2&amp;publication_year=2014&amp;pmid=24439864&amp;doi=10.1016/j.ijcard.2013.12.295&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pone.0330434.ref009">
<span class="label">9.</span><cite>Tan CH, Wu AG, Sia C-H, Leow AS, Chan BP, Sharma VK, et al. Cilostazol for secondary stroke prevention: systematic review and meta-analysis. Stroke Vasc Neurol. 2021;6(3):410–23. doi: 10.1136/svn-2020-000737

</cite> [<a href="https://doi.org/10.1136/svn-2020-000737" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8485237/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33542092/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Stroke%20Vasc%20Neurol&amp;title=Cilostazol%20for%20secondary%20stroke%20prevention:%20systematic%20review%20and%20meta-analysis&amp;author=CH%20Tan&amp;author=AG%20Wu&amp;author=C-H%20Sia&amp;author=AS%20Leow&amp;author=BP%20Chan&amp;volume=6&amp;issue=3&amp;publication_year=2021&amp;pages=410-23&amp;pmid=33542092&amp;doi=10.1136/svn-2020-000737&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pone.0330434.ref010">
<span class="label">10.</span><cite>Lin J-L, Tseng W-K, Lee P-T, Lee C-H, Tseng S-Y, Chen P-W, et al. A Randomized Controlled Trial Evaluating Outcome Impact of Cilostazol in Patients with Coronary Artery Disease or at a High Risk of Cardiovascular Disease. J Pers Med. 2022;12(6):938. doi: 10.3390/jpm12060938

</cite> [<a href="https://doi.org/10.3390/jpm12060938" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9225272/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35743723/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Pers%20Med&amp;title=A%20Randomized%20Controlled%20Trial%20Evaluating%20Outcome%20Impact%20of%20Cilostazol%20in%20Patients%20with%20Coronary%20Artery%20Disease%20or%20at%20a%20High%20Risk%20of%20Cardiovascular%20Disease&amp;author=J-L%20Lin&amp;author=W-K%20Tseng&amp;author=P-T%20Lee&amp;author=C-H%20Lee&amp;author=S-Y%20Tseng&amp;volume=12&amp;issue=6&amp;publication_year=2022&amp;pages=938&amp;pmid=35743723&amp;doi=10.3390/jpm12060938&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pone.0330434.ref011">
<span class="label">11.</span><cite>Morgan CJ. Landmark analysis: A primer. J Nucl Cardiol. 2019;26(2):391–3. doi: 10.1007/s12350-019-01624-z

</cite> [<a href="https://doi.org/10.1007/s12350-019-01624-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30719655/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Nucl%20Cardiol&amp;title=Landmark%20analysis:%20A%20primer&amp;author=CJ%20Morgan&amp;volume=26&amp;issue=2&amp;publication_year=2019&amp;pages=391-3&amp;pmid=30719655&amp;doi=10.1007/s12350-019-01624-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pone.0330434.ref012">
<span class="label">12.</span><cite>Hirsch AT, Hartman L, Town RJ, Virnig BA. National health care costs of peripheral arterial disease in the Medicare population. Vasc Med. 2008;13(3):209–15. doi: 10.1177/1358863X08089277

</cite> [<a href="https://doi.org/10.1177/1358863X08089277" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18687757/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Vasc%20Med&amp;title=National%20health%20care%20costs%20of%20peripheral%20arterial%20disease%20in%20the%20Medicare%20population&amp;author=AT%20Hirsch&amp;author=L%20Hartman&amp;author=RJ%20Town&amp;author=BA%20Virnig&amp;volume=13&amp;issue=3&amp;publication_year=2008&amp;pages=209-15&amp;pmid=18687757&amp;doi=10.1177/1358863X08089277&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pone.0330434.ref013">
<span class="label">13.</span><cite>Agnelli G, Belch JJF, Baumgartner I, Giovas P, Hoffmann U. Morbidity and mortality associated with atherosclerotic peripheral artery disease: A systematic review. Atherosclerosis. 2020;293:94–100. doi: 10.1016/j.atherosclerosis.2019.09.012

</cite> [<a href="https://doi.org/10.1016/j.atherosclerosis.2019.09.012" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31606132/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Atherosclerosis&amp;title=Morbidity%20and%20mortality%20associated%20with%20atherosclerotic%20peripheral%20artery%20disease:%20A%20systematic%20review&amp;author=G%20Agnelli&amp;author=JJF%20Belch&amp;author=I%20Baumgartner&amp;author=P%20Giovas&amp;author=U%20Hoffmann&amp;volume=293&amp;publication_year=2020&amp;pages=94-100&amp;pmid=31606132&amp;doi=10.1016/j.atherosclerosis.2019.09.012&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pone.0330434.ref014">
<span class="label">14.</span><cite>Lim J-H, Woo J-S, Shin Y-W. Cilostazol protects endothelial cells against lipopolysaccharide-induced apoptosis through ERK1/2- and P38 MAPK-dependent pathways. Korean J Intern Med. 2009;24(2):113–22. doi: 10.3904/kjim.2009.24.2.113

</cite> [<a href="https://doi.org/10.3904/kjim.2009.24.2.113" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2698619/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19543489/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Korean%20J%20Intern%20Med&amp;title=Cilostazol%20protects%20endothelial%20cells%20against%20lipopolysaccharide-induced%20apoptosis%20through%20ERK1/2-%20and%20P38%20MAPK-dependent%20pathways&amp;author=J-H%20Lim&amp;author=J-S%20Woo&amp;author=Y-W%20Shin&amp;volume=24&amp;issue=2&amp;publication_year=2009&amp;pages=113-22&amp;pmid=19543489&amp;doi=10.3904/kjim.2009.24.2.113&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pone.0330434.ref015">
<span class="label">15.</span><cite>Sakamoto T, Ohashi W, Tomita K, Hattori K, Matsuda N, Hattori Y. Anti-inflammatory properties of cilostazol: Its interruption of DNA binding activity of NF-κB from the Toll-like receptor signaling pathways. Int Immunopharmacol. 2018;62:120–31. doi: 10.1016/j.intimp.2018.06.021

</cite> [<a href="https://doi.org/10.1016/j.intimp.2018.06.021" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30005227/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20Immunopharmacol&amp;title=Anti-inflammatory%20properties%20of%20cilostazol:%20Its%20interruption%20of%20DNA%20binding%20activity%20of%20NF-%CE%BAB%20from%20the%20Toll-like%20receptor%20signaling%20pathways&amp;author=T%20Sakamoto&amp;author=W%20Ohashi&amp;author=K%20Tomita&amp;author=K%20Hattori&amp;author=N%20Matsuda&amp;volume=62&amp;publication_year=2018&amp;pages=120-31&amp;pmid=30005227&amp;doi=10.1016/j.intimp.2018.06.021&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pone.0330434.ref016">
<span class="label">16.</span><cite>Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation. 1998;98(7):678–86. doi: 10.1161/01.cir.98.7.678

</cite> [<a href="https://doi.org/10.1161/01.cir.98.7.678" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9715861/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Cilostazol%20has%20beneficial%20effects%20in%20treatment%20of%20intermittent%20claudication:%20results%20from%20a%20multicenter,%20randomized,%20prospective,%20double-blind%20trial&amp;author=DL%20Dawson&amp;author=BS%20Cutler&amp;author=MH%20Meissner&amp;author=DE%20Jr%20Strandness&amp;volume=98&amp;issue=7&amp;publication_year=1998&amp;pages=678-86&amp;pmid=9715861&amp;doi=10.1161/01.cir.98.7.678&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pone.0330434.ref017">
<span class="label">17.</span><cite>Collinson DJ, Donnelly R. Cilostazol: improving walking distance in patients with intermittent claudication. Expert Rev Cardiovasc Ther. 2004;2(4):503–9. doi: 10.1586/14779072.2.4.503

</cite> [<a href="https://doi.org/10.1586/14779072.2.4.503" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15225110/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Expert%20Rev%20Cardiovasc%20Ther&amp;title=Cilostazol:%20improving%20walking%20distance%20in%20patients%20with%20intermittent%20claudication&amp;author=DJ%20Collinson&amp;author=R%20Donnelly&amp;volume=2&amp;issue=4&amp;publication_year=2004&amp;pages=503-9&amp;pmid=15225110&amp;doi=10.1586/14779072.2.4.503&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pone.0330434.ref018">
<span class="label">18.</span><cite>Soga Y, Iida O, Kawasaki D, Hirano K, Yamaoka T, Suzuki K. Impact of cilostazol on angiographic restenosis after balloon angioplasty for infrapopliteal artery disease in patients with critical limb ischemia. Eur J Vasc Endovasc Surg. 2012;44(6):577–81. doi: 10.1016/j.ejvs.2012.09.020

</cite> [<a href="https://doi.org/10.1016/j.ejvs.2012.09.020" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23107298/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Vasc%20Endovasc%20Surg&amp;title=Impact%20of%20cilostazol%20on%20angiographic%20restenosis%20after%20balloon%20angioplasty%20for%20infrapopliteal%20artery%20disease%20in%20patients%20with%20critical%20limb%20ischemia&amp;author=Y%20Soga&amp;author=O%20Iida&amp;author=D%20Kawasaki&amp;author=K%20Hirano&amp;author=T%20Yamaoka&amp;volume=44&amp;issue=6&amp;publication_year=2012&amp;pages=577-81&amp;pmid=23107298&amp;doi=10.1016/j.ejvs.2012.09.020&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pone.0330434.ref019">
<span class="label">19.</span><cite>Neel JD, Kruse RL, Dombrovskiy VY, Vogel TR. Cilostazol and freedom from amputation after lower extremity revascularization. J Vasc Surg. 2015;61(4):960–4. doi: 10.1016/j.jvs.2014.11.067

</cite> [<a href="https://doi.org/10.1016/j.jvs.2014.11.067" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25595396/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Vasc%20Surg&amp;title=Cilostazol%20and%20freedom%20from%20amputation%20after%20lower%20extremity%20revascularization&amp;author=JD%20Neel&amp;author=RL%20Kruse&amp;author=VY%20Dombrovskiy&amp;author=TR%20Vogel&amp;volume=61&amp;issue=4&amp;publication_year=2015&amp;pages=960-4&amp;pmid=25595396&amp;doi=10.1016/j.jvs.2014.11.067&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pone.0330434.ref020">
<span class="label">20.</span><cite>Sohn M, Chun EJ, Lim S. Cilostazol treatment for preventing adverse cardiovascular events in patients with type 2 diabetes and coronary atherosclerosis: Long-term follow-up of the ESCAPE study. J Diabetes. 2022;14(8):524–31. doi: 10.1111/1753-0407.13300

</cite> [<a href="https://doi.org/10.1111/1753-0407.13300" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9426278/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35932165/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Diabetes&amp;title=Cilostazol%20treatment%20for%20preventing%20adverse%20cardiovascular%20events%20in%20patients%20with%20type%202%20diabetes%20and%20coronary%20atherosclerosis:%20Long-term%20follow-up%20of%20the%20ESCAPE%20study&amp;author=M%20Sohn&amp;author=EJ%20Chun&amp;author=S%20Lim&amp;volume=14&amp;issue=8&amp;publication_year=2022&amp;pages=524-31&amp;pmid=35932165&amp;doi=10.1111/1753-0407.13300&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="pone.0330434.ref021">
<span class="label">21.</span><cite>Ishii H, Aoyama T, Takahashi H, Kumada Y, Kamoi D, Sakakibara T, et al. Treatment with cilostazol improves clinical outcome after endovascular therapy in hemodialysis patients with peripheral artery disease. J Cardiol. 2016;67(2):199–204. doi: 10.1016/j.jjcc.2015.05.003

</cite> [<a href="https://doi.org/10.1016/j.jjcc.2015.05.003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26074442/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Cardiol&amp;title=Treatment%20with%20cilostazol%20improves%20clinical%20outcome%20after%20endovascular%20therapy%20in%20hemodialysis%20patients%20with%20peripheral%20artery%20disease&amp;author=H%20Ishii&amp;author=T%20Aoyama&amp;author=H%20Takahashi&amp;author=Y%20Kumada&amp;author=D%20Kamoi&amp;volume=67&amp;issue=2&amp;publication_year=2016&amp;pages=199-204&amp;pmid=26074442&amp;doi=10.1016/j.jjcc.2015.05.003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section></section><article class="sub-article" id="pone.0330434.r001"><section class="pmc-layout__citation font-secondary font-xs"><div>PLoS One. doi: <a href="https://doi.org/10.1371/journal.pone.0330434.r001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1371/journal.pone.0330434.r001</a>
</div></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Decision Letter 0</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Paul%20T%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Timir Paul</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Timir Paul</span></h3>
<div>Academic Editor</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Paul%20T%22%5BAuthor%5D" class="usa-link"><span class="name western">Timir Paul</span></a>
</div>
</div>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a.c" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="clp_a.c" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a.c" class="d-panel p" style="display: none">
<h4 class="font-secondary">Roles</h4>
<div class="p">
<strong class="contrib"><span class="name western">Timir Paul</span></strong>: <span class="role">Academic Editor</span>
</div>
</div>
<div id="clp_a.c" class="d-panel p" style="display: none">
<div>© 2025 Timir Paul</div>
<p>This is an open access article distributed under the terms of the <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Creative Commons Attribution License</a> , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div></div>
</div></section><section class="body sub-article-body"><hr class="headless">
<p>
<em>27 Jun 2025</em>
</p>
<p>Dear Dr. Li,</p>
<p>Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.</p>
<p>Please submit your revised manuscript by Aug 11 2025 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <span>plosone@plos.org</span> . When you're ready to submit your revision, log on to <a href="https://www.editorialmanager.com/pone/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.editorialmanager.com/pone/</a> and select the 'Submissions Needing Revision' folder to locate your manuscript file.</p>
<ul class="list" style="list-style-type:disc">
<li><p>A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.</p></li>
<li><p>A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.</p></li>
<li><p>An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.</p></li>
</ul>
<p>If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <a href="https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols</a> . Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at <a href="https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://plos.org/protocols?utm_medium=editorial-email&amp;utm_source=authorletters&amp;utm_campaign=protocols</a> .</p>
<p>We look forward to receiving your revised manuscript.</p>
<p>Kind regards,</p>
<p>Timir Paul</p>
<p>Academic Editor</p>
<p>PLOS ONE</p>
<p>Journal Requirements: </p>
<p>When submitting your revision, we need you to address these additional requirements.</p>
<p>1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at</p>
<p><a href="https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf</a> and</p>
<p><a href="https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf</a> .</p>
<p>2. Thank you for stating the following financial disclosure:</p>
<p> [This work was supported by a grant from the Chung Shan Medical University Hospital (CSH-2-25-D-002, Ting-Hsing Chao).]. </p>
<p>Please state what role the funders took in the study.  If the funders had no role, please state: ""The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.""</p>
<p>If this statement is not correct you must amend it as needed.</p>
<p>Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.</p>
<p>3. We note that you have indicated that there are restrictions to data sharing for this study. For studies involving human research participant data or other sensitive data, we encourage authors to share de-identified or anonymized data. However, when data cannot be publicly shared for ethical reasons, we allow authors to make their data sets available upon request. For information on unacceptable data access restrictions, please see <a href="http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions</a>.</p>
<p>Before we proceed with your manuscript, please address the following prompts:</p>
<p>a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., a Research Ethics Committee or Institutional Review Board, etc.). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.</p>
<p>b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see <a href="http://www.bmj.com/content/340/bmj.c181.long" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://www.bmj.com/content/340/bmj.c181.long</a> for guidelines on how to de-identify and prepare clinical data for publication. For a list of recommended repositories, please see <a href="https://journals.plos.org/plosone/s/recommended-repositories" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://journals.plos.org/plosone/s/recommended-repositories</a>. You also have the option of uploading the data as Supporting Information files, but we would recommend depositing data directly to a data repository if possible.</p>
<p>Please update your Data Availability statement in the submission form accordingly.</p>
<p>4. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section.</p>
<p>5. We notice that your supplementary table is included in the manuscript file. Please remove them and upload them with the file type 'Supporting Information'. Please ensure that each Supporting Information file has a legend listed in the manuscript after the references list.</p>
<p>6. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.</p>
<p>[Note: HTML markup is below. Please do not edit.]</p>
<p>Reviewers' comments:</p>
<p>Reviewer's Responses to Questions</p>
<p>
<strong>Comments to the Author</strong>
</p>
<p>1. Is the manuscript technically sound, and do the data support the conclusions?</p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: Yes</p>
<p>Reviewer #3: Yes</p>
<p>**********</p>
<p>2. Has the statistical analysis been performed appropriately and rigorously? --&gt;?&gt;</p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: I Don't Know</p>
<p>Reviewer #3: I Don't Know</p>
<p>**********</p>
<p>3. Have the authors made all data underlying the findings in their manuscript fully available??&gt;</p>
<p>The <a href="http://www.plosone.org/static/policies.action#sharing" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">PLOS Data policy</a></p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: Yes</p>
<p>Reviewer #3: Yes</p>
<p>**********</p>
<p>4. Is the manuscript presented in an intelligible fashion and written in standard English??&gt;</p>
<p>Reviewer #1: Yes</p>
<p>Reviewer #2: Yes</p>
<p>Reviewer #3: Yes</p>
<p>**********</p>
<p>Reviewer #1: Chang et al. conducted a retrospective cohort study using Taiwan’s National Health Insurance Research Database (NHIRD) from 2012 to 2022. The study was designed to determine whether cilostazol, with or without standard antiplatelet therapy, improves long-term outcomes for patients with lower extremity arterial disease (LEAD) following angioplasty. The authors identified 5,300 stable patients—those who remained event-free for one year post-angioplasty—and applied stabilized inverse probability of treatment weighting (IPTW) and Cox regression to compare cilostazol monotherapy against aspirin/clopidogrel (and combination therapy).</p>
<p>The main findings revealed no statistically significant differences in major adverse cardiovascular events (MACE), major adverse limb events (MALE), or bleeding between the groups (adjusted hazard ratios ~0.84–0.88, p&gt;0.05). However, there was a lower rate of repeat angioplasty in the cilostazol group (hazard ratio ~0.80, p=0.03). The authors concluded that cilostazol provides similar “prognostic benefits and safety” compared to standard therapy, supporting its use in the long-term management of LEAD. This topic is particularly relevant, given the existing gap between clinical trial evidence and guideline recommendations for cilostazol in LEAD.</p>
<p>Reviewer #2: General Comments</p>
<p>This study significantly contributes to understanding cilostazol's long-term effects in LEAD patients post-PTA in a real-world setting. Its strengths lie in using Taiwan's National Health Insurance Research Database (NHIRD), providing a comprehensive and representative view of clinical practice over ten years. The large sample size of 5,300 stable LEAD patients enhances statistical power and allows for robust analysis. The robust statistical methodology, including stabilized Inverse Probability of Treatment Weighting (IPTW) for confounder adjustment and a landmark design to mitigate immortal time bias, significantly strengthens internal validity.</p>
<p>Despite these strengths, inherent limitations exist. As an observational study, there is potential for residual confounding from unmeasured variables (e.g., Rutherford classification, lesion severity, lifestyle factors) not captured in the administrative database. The generalizability is constrained by its reliance on an Asian cohort and a data collection timeframe (2012-2022) that predates widespread adoption of newer cardiometabolic therapies, limiting applicability to contemporary clinical settings. Finally, the interpretation of statistically non-significant findings (e.g., p-values near 0.05) as "potential clinical relevance" requires more cautious phrasing, as it may over-interpret the evidence</p>
<p>Specific Comments</p>
<p>3.1. Title and Abstract</p>
<p>The title is precise, and the abstract is well-structured, summarizing key aspects and findings.</p>
<p>3.2. Introduction</p>
<p>The introduction effectively sets the clinical context, highlights the research gap, and clearly states the study's objective.</p>
<p>3.3. Methods</p>
<p>3.3.1. Study Design and Data Source</p>
<p>A retrospective cohort design utilized Taiwan's NHIRD (2012-2022). The 10-year period allows for long-term outcome evaluation, but evolving medical guidelines may limit contemporary generalizability.</p>
<p>3.3.2. Study Population and Inclusion/Exclusion Criteria</p>
<p>Adult LEAD patients post-PTA were included, identified by ICD codes. A landmark design (6-12 months post-PTA) mitigated immortal time bias. Exclusion of patients with early MACE/MALE focused on a stable cohort, improving internal validity for this subgroup but potentially limiting broader generalizability.</p>
<p>3.3.3. Clinical Outcomes</p>
<p>Primary endpoints were MACE and MALE; secondary endpoints included individual components and a composite bleeding safety outcome, all clearly defined.</p>
<p>3.3.4. Statistical Analysis</p>
<p>Stabilized IPTW successfully adjusted for baseline confounders, achieving covariate balance. Cox proportional hazards models were used, with the proportional hazards assumption verified. Potential residual confounding from unmeasured variables is acknowledged.</p>
<p>3.4. Results</p>
<p>Cilostazol monotherapy significantly reduced repeat PTA (aHR 0.80, p=0.03). A near-significant reduction in GI bleeding was also observed (aHR 0.76, p=0.05). The interpretation of p-values near 0.05 as "near-significant" or "possible directional benefit" is an over-interpretation and should be rephrased. Subgroup analyses generally showed consistent effects.</p>
<p>3.5. Discussion</p>
<p>Cilostazol therapy showed comparable outcomes and safety to conventional antiplatelet therapy, with a significant reduction in repeat angioplasty. High MACE/MALE rates in LEAD patients underscore the need for comprehensive care. Cilostazol's pleiotropic effects are discussed as potential mechanisms.</p>
<p>Limitations are transparently acknowledged: residual confounding from unmeasured variables, general observational study biases, and the data timeframe (2013-2020) limiting generalizability to contemporary practice due to limited adoption of newer therapies. The authors explicitly limit generalizability to Asian populations. Further studies are called for.</p>
<p>3.6. Conclusion</p>
<p>Cilostazol monotherapy provides comparable clinical outcomes and safety to conventional antiplatelet therapy in stable LEAD patients post-PTA, and was associated with reduced repeat revascularization. The phrasing "signals of potential benefit" for non-significant trends should be rephrased more cautiously.</p>
<p>Reviewer #3: The authors aim to compare cilostazol with other antiplatelet therapies for MACE, MALE, composite bleeding outcomes in patients with LEAD undergoing endovascular revascularization. The findings in the study add to current available literature. The limitations of the study are noted.</p>
<p>**********</p>
<p><a href="https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">what does this mean?</a> ). If published, this will include your full peer review and any attached files.</p>
<p>If you choose “no”, your identity will remain anonymous but your review may still be made public.</p>
<p><strong>Do you want your identity to be public for this peer review?</strong> For information about this choice, including consent withdrawal, please see our <a href="https://www.plos.org/privacy-policy" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Privacy Policy</a></p>
<p>Reviewer #1: <strong>Yes: </strong> Roshan Bista</p>
<p>Reviewer #2: No</p>
<p>Reviewer #3: No</p>
<p>**********</p>
<p>[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]</p>
<p>While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <a href="https://pacev2.apexcovantage.com/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://pacev2.apexcovantage.com/</a> . PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <span>figures@plos.org</span></p>
<section class="sm xbox font-sm" id="pone.0330434.s004"><div class="caption p">
<span>Attachment</span><p>Submitted filename: <em>PONE-D-25-23547-RB.pdf</em></p>
</div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12370041/bin/pone.0330434.s004.pdf" data-ga-action="click_feat_suppl" class="usa-link">pone.0330434.s004.pdf</a><sup> (1.5MB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="pone.0330434.s005"><div class="caption p">
<span>Attachment</span><p>Submitted filename: <em>PLOS one Cilostazole peer review (1).docx</em></p>
</div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12370041/bin/pone.0330434.s005.docx" data-ga-action="click_feat_suppl" class="usa-link">pone.0330434.s005.docx</a><sup> (13.7KB, docx) </sup>
</div></div></section></section></article><article class="sub-article" id="pone.0330434.r002"><section class="pmc-layout__citation font-secondary font-xs"><div>PLoS One. 2025 Aug 21;20(8):e0330434. doi: <a href="https://doi.org/10.1371/journal.pone.0330434.r002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1371/journal.pone.0330434.r002</a>
</div></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Author response to Decision Letter 1</h1></hgroup><ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="anp_a.d" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a.d" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="anp_a.d" class="d-panel p" style="display: none"><div class="notes p"><section id="historyfront-stub2" class="history"><p>Collection date 2025.</p></section></div></div>
<div id="clp_a.d" class="d-panel p" style="display: none"><div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div></div>
</div>
<div></div>
</div></section><section class="body sub-article-body"><hr class="headless">
<p>
<em>24 Jul 2025</em>
</p>
<p>Responding letter</p>
<p>Reviewer #1:</p>
<p>Chang et al. conducted a retrospective cohort study using Taiwan’s National Health Insurance Research Database (NHIRD) from 2012 to 2022. The study was designed to determine whether cilostazol, with or without standard antiplatelet therapy, improves long-term outcomes for patients with lower extremity arterial disease (LEAD) following angioplasty. The authors identified 5,300 stable patients—those who remained event-free for one year post-angioplasty—and applied stabilized inverse probability of treatment weighting (IPTW) and Cox regression to compare cilostazol monotherapy against aspirin/clopidogrel (and combination therapy).</p>
<p>The main findings revealed no statistically significant differences in major adverse cardiovascular events (MACE), major adverse limb events (MALE), or bleeding between the groups (adjusted hazard ratios ~0.84–0.88, p&gt;0.05). However, there was a lower rate of repeat angioplasty in the cilostazol group (hazard ratio ~0.80, p=0.03). The authors concluded that cilostazol provides similar “prognostic benefits and safety” compared to standard therapy, supporting its use in the long-term management of LEAD. This topic is particularly relevant, given the existing gap between clinical trial evidence and guideline recommendations for cilostazol in LEAD.</p>
<p>Reply: We thank the reviewer for the clear and accurate summary of our study. We appreciate the recognition of our efforts to evaluate cilostazol’s real-world effectiveness in the long-term management of LEAD. No changes were made to the abstract or main text in response to this comment, as the summary reflects the study design and findings accurately.</p>
<p>Reviewer: 2</p>
<p>General Comments</p>
<p>This study significantly contributes to understanding cilostazol's long-term effects in LEAD patients post-PTA in a real-world setting. Its strengths lie in using Taiwan's National Health Insurance Research Database (NHIRD), providing a comprehensive and representative view of clinical practice over ten years. The large sample size of 5,300 stable LEAD patients enhances statistical power and allows for robust analysis. The robust statistical methodology, including stabilized Inverse Probability of Treatment Weighting (IPTW) for confounder adjustment and a landmark design to mitigate immortal time bias, significantly strengthens internal validity.</p>
<p>Despite these strengths, inherent limitations exist. As an observational study, there is potential for residual confounding from unmeasured variables (e.g., Rutherford classification, lesion severity, lifestyle factors) not captured in the administrative database. The generalizability is constrained by its reliance on an Asian cohort and a data collection timeframe (2012-2022) that predates widespread adoption of newer cardiometabolic therapies, limiting applicability to contemporary clinical settings. Finally, the interpretation of statistically non-significant findings (e.g., p-values near 0.05) as "potential clinical relevance" requires more cautious phrasing, as it may over-interpret the evidence</p>
<p>Reply: Thank you for this valuable comment. We agree that interpertation of non-significant findings requires caution to avoid overstating. In response, we had revised the result section to “ In comparisons between aspirin or clopidogrel monotherapy and combination therapy with cilostazol, there were no statistically significant differences in the incidence of MACE (aHR, 0.87; 95% CI, 0.75–1.00; p = 0.06), MALE (aHR, 1.11; 95% CI, 0.97–1.26; p = 0.12), or composite bleeding (aHR, 0.94; 95% CI, 0.81–1.11; p = 0.26). The confidence interval for MACE approached the threshold for statistical significance.“. Similarly, in the discussion section, we had recives to “ However, dual therapy combining cilostazol with either aspirin or clopidogrel yielded a hazard ratio for MACE (HR 0.87; 95% CI, 0.75–1.00) and stroke (HR 0.78; 95% CI, 0.60–1.00) that were numerically lower, though these did not meet the threshold for statistical significance.“ These revisions reflect a more neutral and objective description of the data, and avoid interpretive language that may overstate the findings. We appreciate the reviewer’s guidance in strengthening the clarity and rigor of our reporting.</p>
<p>Specific Comments</p>
<p>3.1. Title and Abstract</p>
<p>The title is precise, and the abstract is well-structured, summarizing key aspects and findings.</p>
<p>Reply: Thank you for the positive feedback. No changes were made in response to this comment.</p>
<p>3.2. Introduction</p>
<p>The introduction effectively sets the clinical context, highlights the research gap, and clearly states the study's objective.</p>
<p>Reply: Thank you. We made no changes based on this comment.</p>
<p>3.3. Methods</p>
<p>3.3.1. Study Design and Data Source</p>
<p>A retrospective cohort design utilized Taiwan's NHIRD (2012-2022). The 10-year period allows for long-term outcome evaluation, but evolving medical guidelines may limit contemporary generalizability.</p>
<p>Reply: Thank you for highlighting this important point. We fully agree that evolving treatment guidelines and the introfuction of newer therapy may impact the generalizability of our finding. In the limitaiton, we had acknowlegdged this “ Third, the data reflect clinical practice patterns between 2013 and 2020, a period when the adoption of newer cardiometabolic therapies—such as SGLT2 inhibitors, GLP-1 receptor agonists, and low-dose rivaroxaban (2.5 mg)—was limited. Therefore, the generalizability of our findings to more contemporary treatment paradigms may be constrained.“ We believe this statemtn diredctly afresses the reviewre’s concern, and we are happy to revise or expand it further if needed.</p>
<p>3.3.2. Study Population and Inclusion/Exclusion Criteria</p>
<p>Adult LEAD patients post-PTA were included, identified by ICD codes. A landmark design (6-12 months post-PTA) mitigated immortal time bias. Exclusion of patients with early MACE/MALE focused on a stable cohort, improving internal validity for this subgroup but potentially limiting broader generalizability.</p>
<p>Reply: Thank you for your insightful comment. We fully agree that the use of a landmark design was appropriate to mitigate immortal time bias, given our focus on evaluating long-term pharmacologic effects. At the same time, we acknowledge that this approach may reduce generalizability to patients who experience early post-PTA events. To address this point, we had added the following sentence in limitatoin “Fourth, the use of a landmark design mitigated immortal time bias and strengthened internal validity, but may limit generalizability to patients with early post-PTA events.“</p>
<p>3.3.3. Clinical Outcomes</p>
<p>Primary endpoints were MACE and MALE; secondary endpoints included individual components and a composite bleeding safety outcome, all clearly defined.</p>
<p>Reply: Thank you. No changes were needed.</p>
<p>3.3.4. Statistical Analysis</p>
<p>Stabilized IPTW successfully adjusted for baseline confounders, achieving covariate balance. Cox proportional hazards models were used, with the proportional hazards assumption verified. Potential residual confounding from unmeasured variables is acknowledged.</p>
<p>Reply: Thank you for the observation. We agree and have already acknowledged the possibility of residual confounding from unmeasured variables in the limitations section.</p>
<p>3.4. Results</p>
<p>Cilostazol monotherapy significantly reduced repeat PTA (aHR 0.80, p=0.03). A near-significant reduction in GI bleeding was also observed (aHR 0.76, p=0.05). The interpretation of p-values near 0.05 as "near-significant" or "possible directional benefit" is an over-interpretation and should be rephrased. Subgroup analyses generally showed consistent effects.</p>
<p>Reply: Thank you for this helpful suggestion. We agree that p-values close to 0.05 should be interpreted with caution. In response, we had revised the sentence in the Results section to avoid the phrase “near-significant” and to use more neutral language. “While there were no significant differences in the overall incidence of composite bleeding across groups, gastrointestinal bleeding appeared numerically lower in the cilostazol monotherapy group (aHR, 0.76; 95% CI, 0.57–1.01; p = 0.05).“</p>
<p>3.5. Discussion</p>
<p>Cilostazol therapy showed comparable outcomes and safety to conventional antiplatelet therapy, with a significant reduction in repeat angioplasty. High MACE/MALE rates in LEAD patients underscore the need for comprehensive care. Cilostazol's pleiotropic effects are discussed as potential mechanisms.</p>
<p>Reply: We sincerely thank the reviewer for this clear and concise summary, which highlights the main findings and key discussion points of our study. As these aspects have already been thoroughly addressed in the manuscript, no further revisions were made.</p>
<p>Limitations are transparently acknowledged: residual confounding from unmeasured variables, general observational study biases, and the data timeframe (2013-2020) limiting generalizability to contemporary practice due to limited adoption of newer therapies. The authors explicitly limit generalizability to Asian populations. Further studies are called for.</p>
<p>Reply: We appreciate the reviewer’s acknowledgement of our transparent discussion on study limitations and the scope of generalizability. We concur that further research is warranted to extend these findings to broader populations and evolving treatment paradigms.</p>
<p>3.6. Conclusion</p>
<p>Cilostazol monotherapy provides comparable clinical outcomes and safety to conventional antiplatelet therapy in stable LEAD patients post-PTA, and was associated with reduced repeat revascularization. The phrasing "signals of potential benefit" for non-significant trends should be rephrased more cautiously.</p>
<p>Reply: We thank the reviewer for the insightful comment. We agree that given the subgroup analyses and potential selection bias, non-significant trends should be interpreted with caution. Accordingly, we have removed the phrase “signals of potential benefit” from the Conclusion section. The revised conclusion now states: “In addition, cilostazol was associated with a reduced need for repeat revascularization.” We believe this change makes the manuscript’s interpretation more neutral and scientifically appropriate.</p>
<p>Reviewer: 3</p>
<p>The authors aim to compare cilostazol with other antiplatelet therapies for MACE, MALE, composite bleeding outcomes in patients with LEAD undergoing endovascular revascularization. The findings in the study add to current available literature. The limitations of the study are noted.</p>
<p>Reply: We sincerely thank the reviewer for the positive evaluation and recognition of our study’s contribution to the current literature. We also appreciate the acknowledgment of the study’s limitations, which we have addressed in the Discussion section. No additional changes were required in response to this comment.</p>
<section class="sm xbox font-sm" id="pone.0330434.s007"><div class="caption p">
<span>Attachment</span><p>Submitted filename: <em>Response to Reviewers.docx</em></p>
</div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12370041/bin/pone.0330434.s007.docx" data-ga-action="click_feat_suppl" class="usa-link">pone.0330434.s007.docx</a><sup> (29KB, docx) </sup>
</div></div></section></section></article><article class="sub-article" id="pone.0330434.r003"><section class="pmc-layout__citation font-secondary font-xs"><div>PLoS One. doi: <a href="https://doi.org/10.1371/journal.pone.0330434.r003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1371/journal.pone.0330434.r003</a>
</div></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Decision Letter 1</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Paul%20T%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Timir Paul</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Timir Paul</span></h3>
<div>Academic Editor</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Paul%20T%22%5BAuthor%5D" class="usa-link"><span class="name western">Timir Paul</span></a>
</div>
</div>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a.e" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="clp_a.e" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a.e" class="d-panel p" style="display: none">
<h4 class="font-secondary">Roles</h4>
<div class="p">
<strong class="contrib"><span class="name western">Timir Paul</span></strong>: <span class="role">Academic Editor</span>
</div>
</div>
<div id="clp_a.e" class="d-panel p" style="display: none">
<div>© 2025 Timir Paul</div>
<p>This is an open access article distributed under the terms of the <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Creative Commons Attribution License</a> , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div></div>
</div></section><section class="body sub-article-body"><hr class="headless">
<p>
<em>1 Aug 2025</em>
</p>
<p>Impact of Cilostazol on Clinical Outcomes in Lower Extremity Arterial Disease Patients After Angioplasty: A Real-World Analysis</p>
<p>PONE-D-25-23547R1</p>
<p>Dear Dr. Li,</p>
<p>We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.</p>
<p>Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.</p>
<p>An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at <a href="https://www.editorialmanager.com/pone/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Editorial Manager®</a>  and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact <a href="https://plos.my.site.com/s/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">billing support</a> .</p>
<p>If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.</p>
<p>Kind regards,</p>
<p>Timir Paul</p>
<p>Academic Editor</p>
<p>PLOS ONE</p></section></article><article class="sub-article" id="pone.0330434.r004"><section class="pmc-layout__citation font-secondary font-xs"><div>PLoS One. doi: <a href="https://doi.org/10.1371/journal.pone.0330434.r004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1371/journal.pone.0330434.r004</a>
</div></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Acceptance letter</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Paul%20T%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Timir Paul</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Timir Paul</span></h3>
<div>Academic Editor</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Paul%20T%22%5BAuthor%5D" class="usa-link"><span class="name western">Timir Paul</span></a>
</div>
</div>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a.f" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="clp_a.f" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a.f" class="d-panel p" style="display: none">
<h4 class="font-secondary">Roles</h4>
<div class="p">
<strong class="contrib"><span class="name western">Timir Paul</span></strong>: <span class="role">Academic Editor</span>
</div>
</div>
<div id="clp_a.f" class="d-panel p" style="display: none">
<div>© 2025 Timir Paul</div>
<p>This is an open access article distributed under the terms of the <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Creative Commons Attribution License</a> , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div></div>
</div></section><section class="body sub-article-body"><hr class="headless">
<p>PONE-D-25-23547R1</p>
<p>PLOS ONE</p>
<p>Dear Dr. Li,</p>
<p>I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.</p>
<p>At this stage, our production department will prepare your paper for publication. This includes ensuring the following:</p>
<p>* All references, tables, and figures are properly cited</p>
<p>* All relevant supporting information is included in the manuscript submission,</p>
<p>* There are no issues that prevent the paper from being properly typeset</p>
<p>You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps.</p>
<p>Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.</p>
<p>You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at <a href="https://explore.plos.org/phishing" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://explore.plos.org/phishing</a>.</p>
<p>If we can help with anything else, please email us at customercare@plos.org.</p>
<p>Thank you for submitting your work to PLOS ONE and supporting open access.</p>
<p>Kind regards,</p>
<p>PLOS ONE Editorial Office Staff</p>
<p>on behalf of</p>
<p>Dr. Timir Paul</p>
<p>Academic Editor</p>
<p>PLOS ONE</p></section></article><article class="sub-article" id="_ad93_"><section class="pmc-layout__citation font-secondary font-xs"><div></div></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Associated Data</h1></hgroup><ul class="d-buttons inline-list"></ul>
<div class="d-panels font-secondary-light"></div>
<div></div>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
</div></section><section class="body sub-article-body"><section id="_adsm93_" lang="en" class="supplementary-materials"><h2 class="pmc_sec_title">Supplementary Materials</h2>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p">
<span>Supplemental Fig 1. Schematic diagram of the data collection timeline. (LEAD: lower extremities artery disease; MACE: major adverse cardiovascular events; MALE: major adverse limb events; N: number of participants; NOAC: Novel oral anticoagulants; PTA: percutaneous transluminal angioplasty).</span><p>(TIF)</p>
</div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12370041/bin/pone.0330434.s001.tif" data-ga-action="click_feat_suppl" class="usa-link">pone.0330434.s001.tif</a><sup> (62.7KB, tif) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material2_reqid_"><div class="caption p">
<span>Supplemental Fig 2. Subgroup analysis of major adverse cardiovascular events and major adverse limb events between cilostazol plus aspirin or Plavix users and aspirin or Plavix users.</span><p>(TIF)</p>
</div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12370041/bin/pone.0330434.s002.tif" data-ga-action="click_feat_suppl" class="usa-link">pone.0330434.s002.tif</a><sup> (366.6KB, tif) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material3_reqid_"><div class="caption p">
<span>S1 Table. Supplemental table 1. ICD-9 and ICD-10 codes.</span><p>(DOCX)</p>
</div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12370041/bin/pone.0330434.s003.docx" data-ga-action="click_feat_suppl" class="usa-link">pone.0330434.s003.docx</a><sup> (17KB, docx) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material4_reqid_"><div class="caption p">
<span>Attachment</span><p>Submitted filename: <em>PONE-D-25-23547-RB.pdf</em></p>
</div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12370041/bin/pone.0330434.s004.pdf" data-ga-action="click_feat_suppl" class="usa-link">pone.0330434.s004.pdf</a><sup> (1.5MB, pdf) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material5_reqid_"><div class="caption p">
<span>Attachment</span><p>Submitted filename: <em>PLOS one Cilostazole peer review (1).docx</em></p>
</div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12370041/bin/pone.0330434.s005.docx" data-ga-action="click_feat_suppl" class="usa-link">pone.0330434.s005.docx</a><sup> (13.7KB, docx) </sup>
</div></div></section><section class="sm xbox font-sm" id="db_ds_supplementary-material6_reqid_"><div class="caption p">
<span>Attachment</span><p>Submitted filename: <em>Response to Reviewers.docx</em></p>
</div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12370041/bin/pone.0330434.s007.docx" data-ga-action="click_feat_suppl" class="usa-link">pone.0330434.s007.docx</a><sup> (29KB, docx) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h2 class="pmc_sec_title">Data Availability Statement</h2>
<p>The minimal data set required to replicate the findings has been provided via this manuscript's <a href="#sec016" class="usa-link">Supporting Information</a> files. The original data derived from the National Health Insurance Research Database (NHIRD), Taiwan, are not publicly available due to legal and ethical restrictions. Access to these data requires formal application and approval by the Health and Welfare Data Science Center, Ministry of Health and Welfare, Taiwan. Requests for data access can be directed to the Health and Welfare Data Science Center via email (e.g., Mr. Wu at <span>stwu@mohw.gov.tw</span>) or through the official website: <a href="https://dep.mohw.gov.tw/DOS/np-2497-113.html" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://dep.mohw.gov.tw/DOS/np-2497-113.html</a>. The website provides detailed information on data application procedures and official contact points.</p></section></section></article><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from PLOS One are provided here courtesy of <strong>PLOS</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1371/journal.pone.0330434"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/pone.0330434.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (641.6 KB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12370041/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12370041/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12370041%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12370041/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12370041/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12370041/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40839648/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12370041/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40839648/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12370041/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12370041/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="RKmsrpR0fu81o3wL0dnuaixdnhxAGppXZx5c7An52Pi1XUM9mwm4iAKzjWeThCpu">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
